

JC10 Rec'd PCT/PTO 07 JAN 2002

FORM PTO-1390 (REV 5-93)		U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 14187.00001	
INTERNATIONAL APPLICATION NO. PCT/CA00/00801	INTERNATIONAL FILING DATE July 6, 1999 (06.07.2000)	U S APPLICATION NO (If known, see 37 C F R 15) 10/019931	
PRIORITY DATE CLAIMED July 6, 1999 (06.07.99)			
TITLE OF INVENTION METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MODULATING FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER EARLY AND TARDILY			
APPLICANT(S) FOR DO/EO/US Luc VARIN and Satinder GIDDA			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the application time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input checked="" type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 			
Items 11. to 16. below concern other document(s) or information included:			
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information:			

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/019931		INTERNATIONAL APPLICATION NO PCT/CA00/00801	ATTORNEY'S DOCKET NUMBER 14187.00001																	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS																
Basic National Fee (37 CFR 1.492(a)(1)-(5):				PTO USE ONLY																
Search Report has been prepared by the EP or JPO		\$860.00																		
International preliminary examination fee paid to USPTO																				
(37 CFR 1.492(a)(1))		\$690.00																		
No international preliminary examination fee paid to USPTO (37 CFR 1.492																				
(a)(1)) but international search fee paid to USPTO (37 CFR 1.492(a)(2))		\$710.00																		
Neither international preliminary examination fee (37 CFR 1.492(a)(1))																				
nor international search fee (37 CFR 1.492(a)(2)) paid to USPTO		\$1,000.00																		
International preliminary examination fee paid to USPTO (37 CFR 1.492																				
(a)(4)) and all claims satisfied provisions of PCT Article 33(1)-(4)		\$100.00																		
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$1,000.00																
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$130.00																
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Claims</th> <th style="text-align: left;">Number Filed</th> <th style="text-align: left;">Number Extra</th> <th style="text-align: left;">Rate</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>51</td> <td>-20 =</td> <td>31</td> </tr> <tr> <td>Independent Claims</td> <td>13</td> <td>- 3 =</td> <td>10</td> </tr> <tr> <td colspan="3">Multiple dependent claim(s) (if applicable)</td> <td>+ \$270.00</td> </tr> </tbody> </table>				Claims	Number Filed	Number Extra	Rate	Total Claims	51	-20 =	31	Independent Claims	13	- 3 =	10	Multiple dependent claim(s) (if applicable)			+ \$270.00	
Claims	Number Filed	Number Extra	Rate																	
Total Claims	51	-20 =	31																	
Independent Claims	13	- 3 =	10																	
Multiple dependent claim(s) (if applicable)			+ \$270.00																	
TOTAL OF ABOVE CALCULATIONS =				\$2,528.00																
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$1,264.00																
SUBTOTAL =				\$1,264.00																
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$																
TOTAL NATIONAL FEE =				\$1,264.00																
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$																
TOTAL FEES ENCLOSED =				\$0.00																
				Amount to be:																
				refunded \$																
				charged \$1,264.00																
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.																				
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>50-1710</u> in the amount of \$ <u>1,264.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.																				
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-1710</u> . A duplicate copy of this sheet is enclosed.																				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																				
SEND ALL CORRESPONDENCE TO: Patent Administrator		 SIGNATURE																		
KATTEN MUCHIN ZAVIS 525 West Monroe Street, Suite 1600 Chicago, IL 60661-3693 Facsimile: (312) 902-1061		Gilberto M. Villacorta, Ph.D.		Dawn C. Hayes																
		NAME																		
		34,038		44,751																
		REGISTRATION NUMBER																		

FORM PTO-1390 (REV 5-93) U S DEPARTMENT OF COMMERCE-PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 14187.00001
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U S APPLICATION NO (If known, see 37 C F R 1.5) 10/019931
INTERNATIONAL APPLICATION NO. PCT/CA00/00801	INTERNATIONAL FILING DATE July 6, 1999 (06.07.2000)	PRIORITY DATE CLAIMED July 6, 1999 (06.07.99)
TITLE OF INVENTION METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MODULATING FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER EARLY AND TARDILY		
APPLICANT(S) FOR DO/EO/US Luc VARIN and Satinder GIDDA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the application time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input checked="" type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11. to 16. below concern other document(s) or information included:		
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>		

Docket No.: 214187.00500
Customer No. 27160

10/019931
PATENT
Rec'd PCT/PTO 10 MAY 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

VARIN et al.

Serial No. 10/019,931

Group Art Unit: *Unassigned*

Filed: July 6, 2000

Examiner: *Unassigned*

For: METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MODULATING FLOWERING
IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER EARLY AND TARDILY


STATEMENT IN SUPPORT OF SEQUENCE RULE SUBMISSIONS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with PCT Rule 13ter.1(a) and (c), respectively, are the same. Furthermore, I hereby state that the sequence listing does not go beyond the disclosure in the application as filed.

Respectfully submitted,


Dawn C. Hayes
Registration No. 44,751

KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street, Suite 1600
Chicago, IL 60661-3693
Facsimile: (312) 902-1061

Date: May 10, 2002

10/019931
JC13 Rec'd PCT/PTO 07 JAN 2002

14187.00001

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
LUC VARIN, ET AL.) Examiner: Not Yet Assigned
: Group Art Unit: NYA
U.S. National Phase of Int'l.)
Application No.: PCT/CA00/00801:)
Filed: Herewith :
For: METHODS, COMPOSITIONS :
AND GENETIC SEQUENCES)
FOR MODULATING FLOWERING :
IN PLANTS, AND PLANTS)
GENETICALLY MODIFIED TO : January 7, 2002
FLOWER EARLY AND TARDILY)

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination on the merits, please amend
the above-identified application as follows:

IN THE CLAIMS:

Please amend the claims to read as shown below. A
mark-up version showing the changes made to the claims is
attached for the Examiner's convenience.

9. (Amended) The method of claim 5, wherein said plant
is transgenic.

11. (Amended) The method of claim 2, wherein said plant

is selected from crop plants.

14. (Amended) The genetically modified plant of claim 12, wherein said genetic modification comprises inhibiting the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or of *AtST2b*.

17. (Amended) The genetically modified plant of claim 12, wherein said plant is transgenic.

18. (Amended) A cut flower from the genetically modified plant of claim 12.

27. (Amended) The method of claim 21, wherein said plant is transgenic.

31. (Amended) The genetically modified plant of claim 29, wherein said genetic modification comprises increasing the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or *AtST2b*.

33. (Amended) The genetically modified plant of claim 29, wherein said plant is transgenic.

39. (Amended) The isolated nucleic acid molecule of

39. (Amended) The isolated nucleic acid molecule of claim 36, wherein the hydroxyjasmonic acid sulfotransferase is of *Arabidopsis thaliana* origin.

40. (Amended) A vector comprising the nucleic acid molecule of claim 36.

42. (Amended) A transgenic plant comprising the nucleic acid molecule of claim 36.

47. (Amended) The method of claim 43, wherein the hydroxyjasmonic acid sulfotransferase is a 11- or a 12-hydroxyjasmonic acid sulfotransferase.

50. (Amended) An antibody binding with affinity to a polypeptide as defined in claim 48.

REMARKS

Claims 1-51 are pending in this application, with Claims 1, 12, 19, 29, 34, 36, 40, 43, 45, 48 and 50 being independent. Claims 9, 11, 14, 17, 18, 27, 31, 33, 39, 40, 42, 47 and 50 have been amended in this Preliminary Amendment to remove all multiple dependencies.

Applicants respectfully submit that this Amendment places the application in condition for allowance, and request prompt issuance of a Notice thereof. However, if the

urged to contact Applicants' representative at the phone number given below.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 625-3500. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicants
Dawn C. Hayes
Registration No. 44,571

PATENT ADMINISTRATOR
KATTEN MUCHIN ZAVIS
525 West Monroe Street
Suite 1600
Chicago, Illinois 60661-3693
Facsimile: (312) 902-1061

Marked-up version of claims

9. The method of [any one of claims] claim 5 [to 8], wherein said plant is transgenic.
- 5 11. The method of [any one of claims] claim 2 [to 10], wherein said plant is selected from crop plants.
14. The genetically modified plant of claim 12 [or 13], wherein said genetic modification comprises inhibiting the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or of *AtST2b*.
- 10 17. The genetically modified plant of [any one of claims] claim 12 [to 16], wherein said plant is transgenic.
- 15 18. A cut flower from the genetically modified plant of [any one of claims] claim 12 [to 16].
- 20 27. The method of [any one of claims] claim 21 [to 26], wherein said plant is transgenic.
- 25 31. The genetically modified plant of [claims] claim 29 [or 30], wherein said genetic modification comprises increasing the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or *AtST2b*.
33. The genetically modified plant of [any one of claims] claim 29 [or 30], wherein said plant is transgenic.
- 30 39. The isolated nucleic acid molecule of [any one of claims] claim 36 [to 38], wherein the hydroxyjasmonic acid sulfotransferase is of *Arabidopsis thaliana* origin.

Marked-up version of claims

40. A vector comprising the nucleic acid molecule of [any one of claims] claim 36 [to 39].

5 42. A transgenic plant comprising the nucleic acid molecule of [any one of claims] claim 36 [to 39].

10 47. The method of [any one of claims] claim 43 [to 46], wherein the hydroxyjasmonic acid sulfotransferase is a 11- or a 12- hydroxyjasmonic acid sulfotransferase.

50. An antibody binding with affinity to a polypeptide as defined in claim 48 [or 49].

10/019931
PTO/PCT Rec'd 07 JAN 2002

34

SEQUENCE LISTING

<110> VARIN, LUC
GIDDA, SATINDER

<120> METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MODULATING
FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER
EARLY AND TARDILY

<130> 29963-0002

<140> PCT/CA00/00801

<141> 2000-07-06

<150> CA 2,274,873

<151> 1999-07-06

<160> 4

<170> PatentIn version 3.0

<210> 1

<211> 1077

<212> DNA

<213> *Arabidopsis thaliana*

<400> 1	arggctacct	caagcatgaa	gaggattcca	atggcgatcc	caagtttctc	catgtgtcac	60
	aagctcgagc	tcctttaaaga	aggcaaaaact	cgcgacgtcc	cgaaagccga	agaagatgaa	120
	gggctaaagct	gcgagttcca	agagatgttgc	attctcttc	ctaaggagag	aggatggaga	180
	actcgttacc	tttacctatt	ccaagggttt	tggtgccaa	ccaaagagat	tcaagccatc	240
	atgtctttcc	aaaaacattt	ccaatccctc	gaaaacgacg	tcgttctcgc	caccataacct	300
	aaatccggta	caacctggct	aaaagcttta	actttcacca	tccttaaccg	tcaccggttt	360
	gatccggttg	cctcgagttac	caaccaccc	tttttcaatt	ccaaaccctca	tgacccgttga	420
	cctttcttcg	agtacaagct	ttacgccaac	ggagatgttc	ccgatctctc	gggtcttagcc	480
	agtccaaagaa	cgttcgcaac	ccacttaccg	ttcggttccc	taaaggaaac	gatcgagaaa	540
	cccggtgtga	aggtcgtgt	tttgtgcgg	aacccgttttgc	acacattcat	ctttcgtgg	600
	cattacacca	acaacatcaa	atccgagtca	gtgagcccag	tcttgctaga	ccaaagcttt	660
	gatctgtatt	gccggggagt	gatcggtttt	ggcccgtttt	ggaaacacat	gttgggatac	720
	tggagagaga	gtttaaagag	accagagaa	gtcttctttt	taaggtacga	ggatctcaaa	780
	gacgacatcg	agaccaactt	gaagaggctt	gcaacttct	tagagcttcc	tttcaccgaa	840
	gaagaggaac	gaaaggagg	tgtgaaggct	atcgccgagc	tgtgtagctt	cgagaatctg	900
	aagaagttgg	aggtgaacaa	gtcaaacaag	tcgatcaaga	actttgagaa	tcgattcttg	960
	tttcggaaag	gagaagttag	tgattgggtt	aactatttgt	caccattcaca	agtggaaaga	1020

ttgtcagcct tagtgatge caagtttgtt ggatctggtc tcactttcag gttgagc 1077

<210> 2
<211> 1041
<212> DNA
<213> Arabidopsis thaliana

<400> 2
atggcgatcc caagtttctc catgtgtcac aagcccgagc tccttaagga aggcaaaagc 60
gaaggccaaag aagaagaagg gctaagctac gagttccaag agatgttggc ttctcttct 120
aaggagagag gacggagaaa tcgttacctt tacttat-cc aagggtttcg gtgc当地
aaggagattc aagctatcac gtctttccaa aaacatttcc agtcccttcc agacgacgtt 240
gtcctcgcca ccatacctaa atctggcaca acctggtaa aagcttaac tttcaccatc 300
cttacccgtc atcggtttaa tccgggttcc tcataaaggc ttccggccatc 360
tccaaaccctc acgacacctgt acctttcttc gagtacaagc ttacgccaa cggaaatgtt 420
cccgatctct cgggtcttagc cagtc当地 aacatcgccaa cccacgtacc gttcggtgcc 480
cttaaggatt cggtc当地 aacatcgccaa cccacgtacc gttcggtgcc 540
gacacattca tctccatgtg gcattacatc aacaacatca ctccgag-cc agttagcgc当地 600
gtcttgctag acgaagctt tgatctat tgccggggat tactgatcg atttggcccg 660
ttttggaaac acatgttggg atactggaga gagagcttga agaggccaga gaaagtctta 720
tttttaagt acgaggatct caaagaagac atcgagacca actgaaaggc gctagcaagt 780
ttcttaggac ttcccttcac cgaagaagag gaacaaaagg gagttgtgaa agctatcgct 840
gatctgtgttgc gcttggagaa tctggagatc acaagtcaag caaattgtatc 900
cagaactatg acaaccgggtt cttgtttagg aaaggagaag tgagtgttgc ggttaactat 960
ttgtcgccat cacaagtggc aagattgtca gccttagtgg atgacaagtt agctggatct 1020
ggtctcactt tcaagattgag t 1041

<210> 3
<211> 359
<212> PRT
<213> Arabidopsis thaliana

<400> 3

Met Ala Thr Ser Ser Met Lys Ser Ile Pro Met Ala Ile Pro Ser Phe
1 5 10 15

Ser Met Cys His Lys Leu Glu Leu Leu Lys Glu Gly Lys Thr Arg Asp
20 25 30

36

Val Pro Lys Ala Glu Glu Asp Glu Gly Leu Ser Cys Glu Phe Gln Glu
 35 40 45

Met Leu Asp Ser Leu Pro Lys Glu Arg Gly Trp Arg Thr Arg Tyr Leu
 50 55 60

Tyr Leu Phe Gln Gly Phe Trp Cys Gln Ala Lys Glu Ile Gln Ala Ile
 65 70 75 80

Met Ser Phe Gln Lys His Phe Gln Ser Leu Glu Asn Asp Val Val Leu
 85 90 95

Ala Thr Ile Pro Lys Ser Gly Thr Thr Trp Leu Lys Ala Leu Thr Phe
 100 105 110

Thr Ile Leu Asn Arg His Arg Phe Asp Pro Val Ala Ser Ser Thr Asn
 115 120 125

His Pro Leu Phe Thr Ser Asn Pro His Asp Leu Val Pro Phe Phe Glu
 130 135 140

Tyr Lys Leu Tyr Ala Asn Gly Asp Val Pro Asp Leu Ser Gly Leu Ala
 145 150 155 160

Ser Pro Arg Thr Phe Ala Thr His Leu Pro Phe Gly Ser Leu Lys Glu
 165 170 175

Thr Ile Glu Lys Pro Gly Val Lys Val Val Tyr Leu Cys Arg Asn Pro
 180 185 190

Phe Asp Thr Phe Ile Ser Ser Trp His Tyr Thr Asn Asn Ile Lys Ser
 195 200 205

Glu Ser Val Ser Pro Val Leu Leu Asp Gln Ala Phe Asp Leu Tyr Cys
 210 215 220

Arg Gly Val Ile Gly Phe Gly Pro Phe Trp Glu His Met Leu Gly Tyr
 225 230 235 240

Trp Arg Glu Ser Leu Lys Arg Pro Glu Lys Val Phe Phe Leu Arg Tyr
 245 250 255

Glu Asp Leu Lys Asp Asp Ile Glu Thr Asn Leu Lys Arg Leu Ala Thr
 260 265 270

Phe Leu Glu Leu Pro Phe Thr Glu Glu Glu Arg Lys Gly Val Val
 275 280 285

Lys Ala Ile Ala Glu Leu Cys Ser Phe Glu Asn Leu Lys Lys Leu Glu
 290 295 300

Val Asn Lys Ser Asn Lys Ser Ile Lys Asn Phe Glu Asn Arg Phe Leu
 305 310 315 320

Phe Arg Lys Gly Glu Val Ser Asp Trp Val Asn Tyr Leu Ser Pro Ser
 325 330 335

Gln Val Glu Arg Leu Ser Ala Leu Val Asp Asp Lys Leu Gly Gly Ser
 340 345 350

Gly Leu Thr Phe Arg Leu Ser
355

<210> 4
<211> 347
<212> PRT
<213> *Arabidopsis thaliana*

<400> 4

Met Ala Ile Pro Ser Phe Ser Met Cys His Lys Pro Glu Leu Leu Lys
1 5 10 15

Glu Gly Lys Ser Glu Gly Gln Glu Glu Gly Leu Ser Tyr Glu Phe
20 25 30

Gln Glu Met Leu Asp Ser Leu Pro Lys Glu Arg Gly Arg Arg Asn Arg
35 40 45

Tyr Leu Tyr Leu Phe Gln Gly Phe Arg Cys Gln Ala Lys Glu Ile Gln
50 55 60

Ala Ile Thr Ser Phe Gln Lys His Phe Gln Ser Leu Pro Asp Asp Val
65 70 75 80

Val Leu Ala Thr Ile Pro Lys Ser Gly Thr Thr Trp Leu Lys Ala Leu
85 90 95

Thr Phe Thr Ile Leu Thr Arg His Arg Phe Asp Pro Val Ser Ser Ser
100 105 110

Ser Ser Asp His Pro Leu Leu Thr Ser Asn Pro His Asp Leu Val Pro
115 120 125

Phe Phe Glu Tyr Lys Leu Tyr Ala Asn Gly Asn Val Pro Asp Leu Ser
130 135 140

Gly Leu Ala Ser Pro Arg Thr Phe Ala Thr His Val Pro Phe Gly Ala
145 150 155 160

Leu Lys Asp Ser Val Glu Asn Pro Ser Val Lys Val Val Tyr Leu Cys
165 170 175

Arg Asn Pro Phe Asp Thr Phe Ile Ser Met Trp His Tyr Ile Asn Asn
180 185 190

Ile Thr Ser Glu Ser Val Ser Ala Val Leu Leu Asp Glu Ala Phe Asp
195 200 205

Leu Tyr Cys Arg Gly Leu Leu Ile Gly Phe Gly Pro Phe Trp Glu His
210 215 220

Met Leu Gly Tyr Trp Arg Glu Ser Leu Lys Arg Pro Glu Lys Val Leu
225 230 235 240

Phe Leu Lys Tyr Glu Asp Leu Lys Glu Asp Ile Glu Thr Asn Leu Lys
245 250 255

Lys Leu Ala Ser Phe Leu Gly Leu Pro Phe Thr Glu Glu Glu Gln

38

260

265

270

Lys Gly Val Val Lys Ala Ile Ala Asp Leu Cys Ser Phe Glu Asn Leu
275 280 285

Lys Lys Leu Glu Val Asn Lys Ser Ser Lys Leu Ile Gln Asn Tyr Glu
290 295 300

Asn Arg Phe Leu Phe Arg Lys Gly Glu Val Ser Asp Leu Val Asn Tyr
 305 310 315 320

Leu Ser Pro Ser Gln Val Glu Arg Leu Ser Ala Leu Val Asp Asp Lys
 325 330 335

Leu Ala Gly Ser Gly Leu Thr Phe Arg Leu Ser
340 345

**METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MODULATING
FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO
FLOWER EARLY AND TARDILY**

5 BACKGROUND OF THE INVENTION

a) Field of the invention

The invention relates to methods, compositions and genetic sequences to modulate flowering in plants and to plants genetically modified to flower early and 10 plants genetically modified to flower tardily.

b) Brief description of the prior art

In plants, the transition from vegetative to reproductive growth involves complex interactions between several endogenous biochemical pathways. These 15 pathways are continuously evaluating the environmental conditions and the state of growth of the plant. When adequate conditions are met, cross-talk between pathways will ultimately result in the formation of a floral meristem.

For a long time, plant scientists have tried to control floral induction. The results of grafting experiments performed about 70 years ago led to the proposal 20 of a hypothesis which states that a flower inducer, i.e. "a florigen", is synthesized in the leaves and translocated to the shoot apex to induce the development of the flower meristem. However, despite considerable research efforts, the search for the hypothetical "florigen" hormone was unsuccessful. Molecules such as cytokinins, gibberellins and carbon assimilates have also been proposed to act as 25 flowering promoters in some species. For instance, U.S. patents Nos. 5,523,281; 6,020,288 and 6,057,157 disclose various methods and compositions for inducing, accelerating and prolonging flowering in plants or enhancing their growth. However, some of the molecules or compositions described in these patents were 30 found to be inactive or even inhibitory to flower formation in other plant species. Some others are also known to affect the biomass or the plant morphology.

12-hydroxyjasmonic acid (see Fig. 1A) is a natural metabolite and was first isolated from the leaves of *Solanum tuberosum* (potato) (Yoshihara *et al.* (1989),

Agric. Biol. Chem. 53: 2835). The biosynthesis of 12-hydroxyjasmonic acid has not been studied at the biochemical level but recent studies suggest that jasmonic acid is converted to 12-hydroxyjasmonic acid by a single oxidation step catalyzed by the jasmonic acid 12-hydroxylase (Yoshihara *et al.* (1996), Plant Cell Physiol. 37: 586). 11-hydroxyjasmonic acid (see Fig. 1B) is also a natural metabolite for which the mechanism of biosynthesis have not been described either. However, based on the results obtained for the *in vivo* synthesis of 12-hydroxyjasmonic acid, one can predict that a jasmonic acid 11-hydroxylase converts jasmonic acid or methyljasmonic acid into the 11-hydroxylated compounds.

10 Although many functions have been associated with jasmonates metabolites such as 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid, these metabolites have never been associated with flower formation. For instance, U.S. patent No 5,935,809, suggests the use of jasmonate for inducing plant defense mechanisms. U.S. patent No 5,814,581 describes a plant growth 15 promoter composition comprising jasmonate and brassinolide as active ingredients and Japanese patent application No 00292220 (A) published April 3, 1990, Yoshihara *et al.* (1989), Agric. Biol. Chem. 53: 2835-2837, Matsuki *et al.* (1992), Biosci. Biotech. Biochem. 56: 1329.; and Koda and Okazawa (1988), Plant Cell Physiol. 29: 969), suggest the use of 12-hydroxyjasmonic acid for inducing tuber 20 formation in potatoes. None of these documents disclose nor suggest that compounds of the jasmonates family are involved in flower formation pathways.

Accordingly, there is a need for effective methods and compositions to modulate flowering, particularly for plants which are used in the food-processing industry and plants with a horticultural value. There is also a need for plants 25 genetically modified to flower early and for plants genetically modified to flower tardily as well as for methods for producing such genetically modified plants.

SUMMARY OF THE INVENTION

The present invention relates to the modulation of flowering in plants. More 30 particularly, the present invention pertains to methods, compositions and genetic sequences for modulating flowering in plants and to plants genetically modified to flower early and to plants genetically modified to flower tardily.

According to an aspect of the invention, there is provided a method for modulating flowering in a plant. The method comprises the step of modifying in said plant the endogenous level of at least one compound of the jasmonate family, and more particularly compounds selected from the group consisting of jasmonic acid, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, glucoside of 11-hydroxymethyljasmonic acid, sulfate ester of 11-hydroxymethyljasmonic acid, and mixtures thereof.

According to another aspect of the invention, flowering of a plant is induced by increasing in the plant the endogenous level of at one flowering inducing compound selected from the previously mentioned jasmonate family compounds excluding sulfate ester of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, and sulfate ester of 11-hydroxymethyljasmonic acid. In a preferred embodiment, this can be achieved by:

- a) applying to the plant at least one flowering inducing compound and/or salts thereof;
- b) applying to the plant at least one inhibitor of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid;
- c) applying to the plant at least one stimulator of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid;
- d) increasing in the plant the endogenous level of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid; and/or
- e) lowering in the plant the endogenous level of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid.

Alternatively, flowering of a plant can be delayed by lowering the endogenous level in the plant of at least one of the above mentioned flowering inducing compounds. According to an embodiment of the invention this can be achieved by:

- 5 a) applying to the plant an inhibitor and/or an inactivator of at least one of the flowering inducing compounds;
- b) applying to the plant at least one stimulator of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic;
- c) applying to the plant at least one inhibitor of an hydroxylase hydroxylating 10 jasmonic acid and/or methyljasmonic acid;
- d) lowering in the plant the endogenous level of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid; and/or
- e) increasing in the plant the endogenous level of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid.

15 According to another aspect of the invention, compositions for modulating flowering are provided. In an embodiment of the invention, a composition for inducing flowering in a plant is provided, comprising a flowering inducing effective amount of at least one of the previously mentioned flowering inducing compounds or salts thereof, in combination with a diluent or a carrier such that an induction in 20 flowering of the plant occurs when compared to a corresponding plant in the absence of the flowering inducing composition. Similarly, in another embodiment, is provided a flowering delaying composition for delaying flowering in a plant, the composition comprising a flowering delaying effective amount of an inhibitor or of an inactivator of the previously mentioned jasmonate family compounds excluding 25 sulfate ester of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, and sulfate ester of 11-hydroxymethyljasmonic acid, in combination with a diluent or a carrier such that a delay in flowering of said plant occurs when compared to a corresponding plant in the absence of the flowering delaying composition.

30 According to a further aspect of the invention, there are provided genetically modified plants. In an embodiment, a plant is genetically modified to flower early when compared to a corresponding plant not genetically modified. The genetically

modified plant exhibits an increased endogenous level of at least one compound selected from the previously mentioned jasmonate family compounds, excluding sulfate ester of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, and sulfate ester of 11-hydroxymethyljasmonic acid, when compared to a corresponding non-genetically modified plant. In another embodiment a plant is genetically modified to flower tardily when compared to a corresponding plant not genetically modified, the genetically modified plant exhibiting a lowered level of at least one compound selected from the previously mentioned jasmonate family compounds excluding sulfate ester of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, and sulfate ester of 11-hydroxymethyljasmonic acid.

In another aspect, the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a plant hydroxyjasmonic acid sulfotransferase, and more particularly a plant 11- or 12-hydroxyjasmonic acid sulfotransferase. Preferably, the nucleotide sequence is selected from the group consisting of SEQ ID NO:1, nucleotide sequences having at least 50% similarity with SEQ ID NO:1, SEQ ID NO:2 nucleotide sequences having at least 50% similarity with SEQ ID NO:2, and sequences hybridizing under low stringency conditions to one or more of these sequences. Advantageously, these sequences are incorporated into a vector.

According to a related aspect, the invention provides transgenic plants incorporating at least one of these nucleotide sequences so that the transgenic plants are capable of flowering early or tardily. The invention also provides methods for producing such transgenic plants.

An advantage of the present invention is that it allows to modulate flowering in plants without decreasing yield or modifying plant morphology. According to the invention it is possible to inhibit flowering in crop plants such as sugarcane, sugar beets or lettuce, just to mention a few, and thereby increase the taste, sweetness, and tenderness of these agricultural products. On the other hand, it is also possible according to the present invention, to induce flowering which is an

advantage of great economic importance for horticultural plants and some crop plants such as cauliflower and broccoli.

Other objects and advantages of the present invention will be apparent upon reading the following non-restrictive description of several preferred 5 embodiments, made with reference to the accompanying drawings and to the enclosed examples.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B show the chemical structures of 12-hydroxyjasmonic acid 10 (Fig. 1A) and 11-hydroxyjasmonic acid (Fig. 1B).

Figures 2A and 2B are pictures showing the effect on flowering time of a treatment with 12-hydroxyjasmonic acid (Fig. 2B) in *Arabidopsis thaliana*, when compared to a treatment with water (Fig. 2A).

Figure 3 is a picture showing the phenotype of transgenic *Arabidopsis* plants 15 expressing *AtST2a* gene under the control of a constitutive promoter when compared to wild type non-transgenic plant (WT). S5, S6, S9, and S16 indicate independent transgenic lines.

Figure 4 is a Western blot of protein extracts from the plants shown in Fig. 3 probed with anti-*AtST2a* antibodies. MW: Molecular weight markers; WT: wild 20 type plants; S5, S6, S9, and S16: independent transgenic lines.

Figure 5 is a picture showing the phenotype of transgenic *Arabidopsis* plants expressing the *AtST2a* gene in the antisense orientation under the control of a constitutive promoter (TL 7-2-5) when compared to non transgenic plants (WT).

Figure 6 is a picture showing the effect of methyljasmonic acid treatment on 25 the flowering time of wild type *Arabidopsis thaliana* plants (WT C24) and on transgenic *Arabidopsis thaliana* plants expressing the *AtST2a* gene in the antisense orientation under the control of a constitutive promoter (TL 7-2-5).

Figure 7: Shows nucleotide sequence of *AtST2a* gene (SEQ ID NO 1) taken 30 from *Arabidopsis thaliana* database at Stanford University (clone number MOJ9, gene MOJ9.16 and the EST 119G6T7) and the GenBank™ database (accession number AB010697, nucleotides 53936 to 55015).

AMENDED SHEET

Figure 8: Shows the deduced amino acid sequence (SEQ ID NO 3) of the protein encoded by the *AtST2a* gene shown in Fig. 7.

5 **Figure 9:** Shows the nucleotide sequence of *AtST2b* gene (SEQ ID NO 2) taken from *Arabidopsis thaliana* database at Stanford University (clone number MOJ9, gene MOJ9.15) and the GenBank™ database (accession number AB010697, nucleotides 50627 to 51670).

10 **Figure 10:** Shows the deduced amino acid sequence (SEQ ID NO 4) of the protein encoded by the *AtST2b* gene shown in Fig. 9.

15 **Figure 11** is a Northern blot of plants mRNA extracts showing the effect of various 12-hydroxyjasmonate concentrations on the expression of the *AtST2a* gene.

Figure 12 is a Northern blot of plants mRNA extracts showing the effect of the photoperiod on the expression of the *AtST2a* gene.

15 DETAILED DESCRIPTION OF THE INVENTION

A) Definitions

In order to provide an even clearer and more consistent understanding of the specification and the claims, including the scope given herein to such terms, the following definitions are provided:

20 **11-hydroxyjasmonic acid:** 3-Oxo-2-(4-hydroxy-2-pentenyl)-cyclopentane-1-acetic acid. Its chemical structure is shown in Fig. 1B.

11-hydroxyjasmonic acid glucoside: 3-Oxo-2-(4- β -D-glucopyranosyloxy-2-pentenyl)-cyclopentane-1-acetic acid

25 **11-hydroxyjasmonic acid sulfate:** 3-Oxo-2-(4-hydroxysulfonyloxy-2-pentenyl)-cyclopentane-1-acetic acid

12-hydroxyjasmonic acid: 3-Oxo-2-(5-hydroxy-2-pentenyl)-cyclopentane-1-acetic acid. Its chemical structure is shown in Fig. 1A.

12-hydroxyjasmonic acid glucoside: 3-Oxo-2-(5- β -D-glucopyranosyloxy-2-pentenyl)-cyclopentane-1-acetic acid.

30 **12-hydroxyjasmonic acid sulfate:** 3-Oxo-2-(5-hydroxysulfonyloxy-2-pentenyl)-cyclopentane-1-acetic acid.

AMENDED SHEET

5 **Antisense:** Refers to nucleic acids molecules capable of regulating the expression of a corresponding gene in a plant. An antisense molecule as used herein may also encompass a gene construct comprising a structural genomic gene, a cDNA gene or part thereof in reverse orientation relative to its or another promoter. Typically antisense nucleic acid sequences are not templates for protein synthesis but yet interact with complementary sequences in other molecules (such as a gene or RNA) thereby causing the function of those molecules to be affected.

10 **Delay or retard or tardily:** When used in conjunction with the term flowering, it refers to the increase of the time of vegetative growth before flowering of a plant. A flowering delay may be observed when compared with a corresponding plant where flowering has not been delayed.

15 **Effective amount:** Refers to the amount or concentration of a suitable compound that is administered to a plant such that the compound induces or delays flowering of a plant.

20 **Exogenous nucleic acid:** A nucleic acid sequence (such as cDNA, cDNA fragments, genomic DNA fragments, antisense RNA, oligonucleotide) which is not normally part of a plant genome. The "exogenous nucleic acid" may be from any organism or purely synthetic. Typically, the "exogenous nucleic acid sequence" encodes a plant gene such as a *AtST2a*, *AtST2b* or functional homologues of these genes.

25 **Expression:** The process whereby an exogenous nucleic acid, such as a nucleic acid sequence encoding a gene, is transcribed into a mRNA and afterwards translated into a peptide or a protein, in order to carry out its function, if any.

30 **Flowering:** Refers to the appearance of a flower bud in a plant. As it is known, the flower bud will eventually mature to a flower.

Functional homologue: Refers to a molecule having at least 50%, more preferably at least 55%, even more preferably at least 60%, still more preferably at least 65-70%, and yet even more preferably greater than 85% similarity at the level of nucleotide or amino acid sequence to at least one or more regions of a given nucleotide or amino acid sequence. According to preferred embodiments of the present invention, the terms "functional homologue" refer to proteins or nucleic

acid sequences encoding an enzyme having a substantially similar biological activity as 11- or 12-hydroxyjasmonate sulfotransferase and isoenzyme(s) thereof. Such a functional homologue may exist naturally or may be obtained following a single or multiple amino acid substitutions, deletions and/or additions relative to 5 the naturally occurring enzyme(s) using methods and principles well known in the art. A functional homologue of a protein may or may not contain post-translational modifications such as covalently linked carbohydrate, if such modification is not necessary for the performance of a specific function. It should be noted, however, that nucleotide or amino acid sequences may have similarities below the above 10 given percentages and still encode a 11- or 12-hydroxyjasmonate sulfotransferase-like molecule, and such molecules may still be considered within the scope of the present invention where they have regions of sequence conservation.

Genetic/nucleotide sequence: These terms are used herein in their most 15 general sense and encompass any contiguous series of nucleotide bases encoding directly, or via a complementary series of bases, a sequence of amino acids comprising a hydroxyjasmonic acid sulfotransferase molecule, and more particularly a 11- or 12-hydroxyjasmonic acid sulfotransferase. Such a sequence of amino acids may constitute a full-length 11- or 12-hydroxyjasmonic acid 20 sulfotransferase such as is set forth in SEQ ID No:1 and SEQ ID No:2 or an active truncated form thereof or a functional mutant, derivative, part, fragment, homologue or analogue thereof, or may correspond to a particular region such as an N-terminal, C-terminal or internal portion of the enzyme.

Genetic modification or genetic engineering: Refers to the introduction 25 of an exogenous nucleic acid into one or more plant cells to create a genetically modified plant. Methods for genetically modifying a plant are well known in the art. In some cases, it may be preferable that the genetic modification is permanent such that the genetically modified plant may regenerate into whole, sexually 30 competent, viable genetically modified plants. A plant genetically modified in a permanent manner would preferably be capable of self-pollination or cross-pollination with other plants of the same species, so that the exogenous nucleic

acid, carried in the germ line, may be inserted into or bred into agriculturally useful plant varieties.

Endogenous level(s): Refers to the concentration of a given substance which is normally found in a plant (intrinsic) at a given time and stage of growth.

5 Reference herein is made to the altering of the endogenous level of a compound or of an enzyme activity relating to an elevation or reduction in the compound's level or enzyme activity of up to 30% or more preferably of 30-50%, or even more preferably 50-75% or still more preferably 75% or greater above or below the normal endogenous or existing levels. The levels of a compound or the levels of 10 activity of an enzyme can be assayed using known method and techniques.

Isolated nucleic acid molecule: Means a genetic sequence in a non-naturally-occurring condition. Generally, this means isolated away from its natural state or formed by procedures not necessarily encountered in its natural environment. More specifically, it includes nucleic acid molecules formed or 15 maintained *in vitro*, including genomic DNA fragments, recombinant or synthetic molecules and nucleic acids in combination with heterologous nucleic acids such as heterologous nucleic acids fused or operably-linked to the genetic sequences of the present invention. The term "isolated nucleic acid molecule" also extends to the genomic DNA or cDNA or part thereof, encoding a hydroxyjasmonic acid

20 sulfotransferase, preferably a 11- or 12-hydroxyjasmonic acid sulfotransferase, or a functional mutant, derivative, part, fragment, homologue or analogue of 11- or 12-hydroxyjasmonic acid sulfotransferase in reverse orientation relative to its or another promoter. It further extends to naturally-occurring sequences following at 25 least a partial purification relative to other nucleic acid sequences. The term isolated nucleic acid molecule as used herein is understood to have the same meaning as nucleic acid isolate.

Induce or increase: When used in conjunction with the term flowering, it refers to the reduction of the time of vegetative growth before flowering of a plant. A flowering induction may be observed when compared with a corresponding plant 30 wherein flowering has not been induced.

Modulation: Refers to the process by which a given variable is regulated to a certain proportion. According to preferred embodiments of the present invention,

the term "modulate" refers in some cases to induction and in other cases delay, of flowering of a plant.

Plant: refers to a whole plant or a part of a plant comprising, for example, a cell of a plant, a tissue of a plant, an explant, or seeds of a plant. This term further 5 contemplates a plant in the form of a suspension culture or a tissue culture including, but not limited to, a culture of calli, protoplasts, embryos, organs, organelles, etc.

Similarity/Complementarity: In the context of nucleic acid sequences, these terms mean a hybridizable similarity under low, alternatively and preferably 10 medium and alternatively and most preferably high stringency conditions, as defined below. Such a nucleic acid is useful, for example, in screening hydroxyjasmonic acid sulfotransferase genetic sequences, preferably a 11- or 12-hydroxyjasmonic acid sulfotransferase genetic sequences from various sources or for monitoring an introduced genetic sequence in a transgenic plant. The preferred 15 oligonucleotide is directed to a conserved hydroxyjasmonic acid sulfotransferase, preferably a 11- or 12-hydroxyjasmonic acid sulfotransferase genetic sequence or a sequence conserved within a plant genus, plant species and/or plant cultivar or variety.

Stringency: For the purpose of defining the level of stringency, reference 20 can conveniently be made to Maniatis et al. (1982) at pages 387-389, and especially paragraph 11. A low stringency is defined herein as being in 4-6X SSC/1% (w/v) SDS at 37-45 °C for 2-3 hours. Depending on the source and concentration of nucleic acid involved in the hybridization, alternative conditions of 25 stringency may be employed such as medium stringent conditions which are considered herein to be 1-4X SSC/0.5-1% (w/v) SDS at greater than or equal to 45°C for 2-3 hours or high stringent conditions considered herein to be 0.1-1X SSC/0.1-1.0% SDS at greater than or equal to 60° C. for 1-3 hours.

Transformed plant: Refers to introduction of an exogenous nucleic acid, typically a gene, into a whole plant or a part thereof, and expression of the 30 exogenous nucleic acid in the plant.


Transgenic plant: Refers to a whole plant or a part thereof stably transformed with an exogenous nucleic acid introduced into the genome of an individual plant cell using genetic engineering methods.

Vector: A self-replicating RNA or DNA molecule which can be used to transfer an RNA or DNA segment from one organism to another. Vectors are particularly useful for manipulating genetic constructs and different vectors may have properties particularly appropriate to express protein(s) in a recipient during cloning procedures and may comprise different selectable markers. Bacterial plasmids are commonly used vectors. Preferably, the vectors of the invention are capable of facilitating transfer of a nucleic acid into a plant cell and/or facilitating integration into a plant genome.

B) General overview of the invention

The present inventors have now discovered that compounds of the jasmonate family are involved in the flowering of plants. They have also characterized the biological function of two highly homologous genes from *A. thaliana* (*AtST2a* and *AtST2b*) which encode enzymes that inactivate by sulfonation the biological activity of 11-hydroxyjasmonic acid and 12-hydroxyjasmonic acid. The inventors have also determined that expression of the *AtST2a* gene is under the control of photoperiod. These properties suggest that flowering could be induced or delayed, and yield to the elaboration of the following model which is given for purposes of clarification and not to limit the scope of the present invention.

Proposed model for the control of flower induction in plants:



5 Using methods, compositions and genetically modified plants the present application demonstrates that flowering can actually be modulated in plants.

According to an aspect of the invention, flowering of a plant is modulated by modifying in the plant the endogenous level of at least one compound of the jasmonate family selected from the group consisting of jasmonic acid, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, glucoside of 11-hydroxymethyljasmonic acid, and sulfate ester of 11-hydroxymethyljasmonic acid.

In practice, flowering modulation is achieved in two different ways: it is induced or it is delayed. Although many approaches may be used to achieve these effects, the approaches described hereinafter are preferably used according to the invention.

1) Chemical approach*i) Flowering induction*

According to the invention, flowering is induced by increasing in a plant the endogenous level of at least one given flowering inducing compound of the

jasmonate family selected preferably from the group consisting of jasmonic acid, 5 jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-10 hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid. All 15 these compounds have been tested for their biological activity and all of them have been shown to induce flowering at various levels (data not shown). More preferably, levels of 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid are increased. The flowering induction and the endogenous level increased is detectable when compared to a corresponding plant in which the endogenous level of said compound has not been modified. However, it could be preferable in some cases to genetically modify a plant to induce its flowering prior to apply 20 thereto a product or composition further inducing its flowering. The increase of the endogenous level would then have to be compared with the endogenous level of the genetically modified plant in which flowering has previously been induced.

According to a preferred embodiment of the invention, the endogenous level of a selected jasmonate compound is increased by:

25 a) applying to the plant at least one selected jasmonate compound and/or salts thereof;

b) applying to the plant at least one inhibitor of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic; and/or

c) applying to the plant at least one stimulator of an hydroxylase hydroxylating 30 jasmonic acid and/or methyljasmonic acid.

More preferably, the selected jasmonate compound which is applied is 12-hydroxyjasmonic acid or 11-hydroxyjasmonic acid. However, amino acid

conjugates, glucosides, sulfate esters, salts, derivatives or any others natural or chemically synthesized compounds having a similar biological activity on flowering induction, is suitable according to the invention. For instance, inactive compounds such sulfate ester of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, and sulfate ester of 11-hydroxymethyljasmonic acid could be applied to a plant and it is possible that the bacterial or fungal flora of the plant or of its soil would hydrolyze these compounds in active jasmonate compounds. Any of the above mentioned compounds can be applied in a pure form or as a mixture of a plurality of compounds.

Inhibitors of hydroxyjasmonic acid sulfotransferase(s) should prevent *in vivo* inactivation of the flower-inducing molecule by sulfonation. To the contrary, stimulators of jasmonic acid hydroxylase(s) should help in the production of jasmonate family compound(s).

The above mentioned jasmonate compounds, stimulators and/or inhibitors can be part of a composition for inducing flowering in a plant. Such a composition would comprise a flowering inducing effective amount of at least one selected jasmonate compound, in combination with a diluent or a carrier. The compound(s) and their amount would be selected such that an early flowering of the plant would occur following application of the flower inducing composition when compared to a corresponding plant in the absence of said compound(s).

The carrier or diluent can be a solvent such as water, oil or alcohol. The composition may also comprise others active agents such as fertilizers and growth regulators. The inducing composition may also be formulated with emulsifying agents in the presence or absence of fungicides or insecticides, if required. The precise amount of compound employed in the practice of the present invention will depend upon the type of response desired, the formulation used and the type of plant treated. In the following examples, the plant culture medium was supplemented with about 10 μ M of 12-hydroxyjasmonate or with 50 μ M methyljasmonic acid for flowering induction.

i) Flowering retardation

According to the invention, flowering is delayed by lowering the endogenous level in a plant of at least one given compound of the jasmonate family selected preferably from the group consisting of jasmonic acid, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid. More preferably, the levels of 12-hydroxymethyljasmonic acid and of 11-hydroxymethyljasmonic acid are reduced. The flowering delay and the endogenous level lowering is detectable when compared to a corresponding plant in which the endogenous level of the compound has not been modified. However, it could be preferable in some cases to genetically modify a plant to delay its flowering prior to apply thereto a product or composition further delaying its flowering. The lowering of the endogenous level would then have to be compared with the endogenous level of the genetically modified plant in which flowering has previously been delayed.

According to a preferred embodiment of the invention, the endogenous level of a selected jasmonate compound is lowered by:

- a) applying to the plant at least one inhibitor and/or an inactivator of a selected jasmonate compound;
- b) applying to the plant at least one stimulator of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid; and/or
- c) applying to the plant at least one inhibitor of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid.

Inhibitor(s) and/or an inactivator(s) of jasmonate compounds should block or inhibit the biological activity of jasmonate compound(s).

Stimulator(s) of hydroxyjasmonic acid sulfotransferase(s) should stimulate *in vivo* inactivation of the flower-inducing molecule by sulfonation. To the contrary,

inhibitors of jasmonic acid hydroxylase(s) should prevent the production of hydroxylated jasmonate compound(s).

As for the flowering compounds, the above stimulators and/or inhibitors can be applied in a pure form, as a mixture of a plurality of compounds or be part of a 5 flowering delaying composition.

2) Molecular approach

In accordance with the present invention, genetic sequences encoding a plant hydroxyjasmonic acid sulfotransferase have been identified, cloned and used 10 to generate transgenic plants.

SEQ ID NO 1 (Fig. 7; GenBank™: accession number AB010697, nucleotides 53936 to 55015; and Stanford University *Arabidopsis thaliana* database: clone number MOJ9, gene MOJ9.16 and EST 119G6T7) corresponds to the gene *AtST2a* in *Arabidopsis thaliana*. SEQ ID NO 3 (Fig. 8) is an amino acid sequence deduced from SEQ ID NO 1. This amino acid sequence is of public 15 domain and comes from the Kazusa Arabidopsis Opening Site (KAOS) of the Kazusa DNA Research Institute (KDRI) (<http://www.kazusa.or.jp/kaos/>; clone number MOJ9, gene MOJ9.16). The present inventors have found that the *AtST2a* gene from *Arabidopsis thaliana* encodes a sulfotransferase that sulfonates 12-hydroxyjasmonic acid and 11-hydroxyjasmonic acid with high specificity. Although 20 not shown, results obtained demonstrated that this hydroxyjasmonic acid sulfotransferase exhibits high affinity for its substrate with a *Km* value of 11 μ M for 12-hydroxyjasmonic acid and 60 μ M for 11-hydroxyjasmonic acid. The enzyme did not accept structurally related compounds such as cucurbitic acid, arachidonyl 25 alcohol or prostaglandins. Maximum enzyme activity was observed at pH 7.5 in Tris/HCl buffer and did not require divalent cations for activity. The purified recombinant protein expressed in *E. coli* migrated in SDS-PAGE at a position corresponding to approximately 35,000 daltons (see Fig. 4).

SEQ ID NO 2 (Fig. 9; GenBank™: accession number AB010697, nucleotides 30 50627 to 51670; and Stanford University *Arabidopsis thaliana* database: clone number MOJ9 gene MOJ9.15), corresponds to the gene *AtST2b* in *Arabidopsis thaliana*. SEQ ID NO 4 (Fig. 10) is an amino acid sequence deduced from SEQ ID

AMENDED SHEET

NO 1. This amino acid sequence is of public domain and comes from the Kazusa Arabidopsis Opening Site (KAOS) of the Kazusa DNA Research Institute (KDRI) (<http://www.kazusa.or.jp/kaos/>; clone number M0J9, gene MOJ9.15). Amino acid sequence alignment between SEQ ID NOS 3 and 4 indicates that they share 85% 5 amino acid sequence identity and 92% similarity, suggesting that *AtST2a* and *AtST2b* are functional homologues encoding isoenzymes.

Accordingly, one aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a plant hydroxyjasmonic acid sulfotransferase enzyme. More 10 particularly, the present invention is directed to an isolated nucleic acid molecule comprising a nucleotide sequence preferably selected from the group consisting of SEQ ID NO:1, nucleotide sequences having at least 50% similarity with SEQ ID NO:1, SEQ ID NO:2, nucleotide sequences having at least 50% similarity with SEQ ID NO:2, and sequences hybridizing under low stringency conditions to one 15 or more of theses sequences.

The nucleic acid molecules contemplated herein may exist in either orientation alone or in combination with a vector and preferably an expression-vector capable of facilitating transfer and expression of the nucleic acid into the plant cell and/or facilitating integration into the plant genome. Such a vector may, 20 for example, be adapted for use in electroporation, microprojectile bombardment, Agrobacterium-mediated transfer or insertion via DNA or RNA viruses. The vector and/or the nucleic acid molecule contained therein may or may not need to be stably integrated into the plant genome. The vector may also replicate and/or express in prokaryotic cells. Preferably, the vector molecules or parts thereof are 25 capable of integration into the plant genome. The nucleic acid molecule and/or the vector may additionally contain a promoter sequence capable of directing expression of the nucleic acid molecule in a plant cell. The nucleic acid molecule and/or the vector may also be introduced into the cell by any number of means such as those described above. The vector may also comprise a genetic 30 sequence encoding a ribozyme capable of cleaving a hydroxyjasmonic acid sulfotransferase mRNA transcript.

The present invention is exemplified using nucleic acid sequences derived from *Arabidopsis thaliana* since this plant is commonly studied in and it represents a convenient and easily accessible source of material. However, one skilled in the art will immediately appreciate that similar sequences can be isolated from any 5 number of sources such as other plants or certain microorganisms (e.g. fungi or bacteria). All such nucleic acid sequences encoding directly or indirectly a hydroxyjasmonic acid sulfotransferase are encompassed by the present invention regardless of their source. Examples of other suitable sources of genes encoding hydroxyjasmonic acid sulfotransferase include, but are not limited to *Brassica* 10 *napus*, *Brassica oleracea* and *Brassica juncea*.

i) *Flowering induction*

An aspect of the invention contemplates a plant genetically modified to flower early when compared to a corresponding plant not genetically modified, 15 wherein the genetically modified plant has an increased endogenous level of at least one given compound of the jasmonate family selected preferably from the group consisting of jasmonic acid, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine 20 conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid, when compared to the corresponding non-genetically 25 modified plant.

In a preferred embodiment, the endogenous level of the selected jasmonate compound is increased by:

- a) increasing in the plant the endogenous level of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid; and/or
- 30 b) lowering in the plant the endogenous level of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid.

According to a preferred embodiment of the invention this is achieved by genetically modifying the plant so as to lower the expression of the sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid, and functional homologues of this sulfotransferase. More preferably, the 5 plant is modified for inhibiting or blocking the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or of *AtST2b*.

Many methods for inhibiting expression of genes in plants are well known in the art, such as techniques using ribozymes, targeted mutagenesis, T-DNA 10 insertion mutagenesis, and antisense techniques to name a few, and these methods could be used to reduce the present invention in practice. According to a preferred embodiment of the invention, the expression of one of the above mentioned gene is inhibited by providing a transgenic plant expressing an exogenous nucleic acid sequence antisense to this gene. More preferably, the 15 endogenous level of the sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid is lowered by expressing into a genetically modified plant an exogenous nucleic acid sequence, the exogenous nucleic acid sequence encoding i) for a nucleic acid sequence antisense to a gene encoding at least one of said sulfotransferases or ii) for a nucleic acid sequence antisense to a 20 fragment of this gene.

Accordingly, another aspect of the invention contemplates a method for producing a transgenic plant with reduced endogenous or existing hydroxyjasmonic acid sulfotransferase activity, such transgenic plant thereby being capable of flowering early. Preferably, the altered level would be less than 25 the endogenous or existing level of activity in a comparable non-transgenic plant.

According to one embodiment, the method comprises the steps of:

- a) introducing into a cell of a suitable plant an exogenous nucleic acid molecule comprising a sequence of nucleotides antisense to a sequence encoding a plant hydroxyjasmonic acid sulfotransferase, preferably a 11- or 12-hydroxyjasmonic acid sulfotransferase;
- 30 b) regenerating a transgenic plant from the cell; and where necessary

c) growing the transgenic plant for a time and under conditions sufficient to permit expression of the antisense sequence and thereby inhibiting expression of the hydroxyjasmonic acid sulfotransferase.

In a related embodiment, the method for producing a transgenic plant with 5 reduced endogenous or existing hydroxyjasmonic acid sulfotransferase activity comprises the step of altering the hydroxyjasmonic acid sulfotransferase gene(s), preferably the 11- or 12-hydroxyjasmonic acid sulfotransferase gene, through modification of the endogenous sequences via homologous recombination from an appropriately altered hydroxyjasmonic acid sulfotransferase gene or derivative or 10 part thereof introduced into the plant cell, and regenerating a transgenic plant from the cell.

ii) Flowering retardation

An aspect of the invention contemplates a plant, genetically modified to 15 flower tardily when compared to a corresponding plant not genetically modified, wherein the genetically modified plant has a lowered endogenous level of at least one given compound of the jasmonate family selected preferably from the group consisting jasmonic acid, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-20 isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-25 hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid, when compared to the corresponding non-genetically modified plant.

In a preferred embodiment, the endogenous level of the selected jasmonate compound is lowered by:

a) lowering in the plant the endogenous level of an hydroxylase hydroxylating 30 jasmonic acid and/or methyljasmonic acid; and/or
b) increasing in the plant the endogenous level of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid.

According to a preferred embodiment of the invention this is achieved by genetically modifying the plant so as to increase the expression of the sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid, or functional homologues of this sulfotransferase. More preferably, the plant 5 is modified to increase the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or of *AtST2b*.

Methods for increasing expression of genes in plants are well known in the art, such as activation tagging, transgenesis under the control of a strong promoter, and these methods could be used to reduce the present invention in 10 practice. According to a preferred embodiment of the invention, the expression of one of the above-mentioned genes is increased by expressing into the plant a gene expressing the sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic under the control of a constitutive or an inducible promoter.

Accordingly, another aspect of the invention contemplates a method for 15 producing a transgenic plant with increased endogenous or existing hydroxyjasmonic acid sulfotransferase activity, such transgenic plant thereby being capable of flowering tardily. Preferably, the altered level would be higher than the endogenous or existing level of activity in a comparably non-transgenic plant.

20 According to a preferred embodiment, the method comprises the step of:

- introducing into a cell of a suitable plant an exogenous nucleic acid molecule comprising a sequence of nucleotides encoding a plant hydroxyjasmonic acid sulfotransferase, preferably a 11- or 12-hydroxyjasmonic acid sulfotransferase;
- regenerating a transgenic plant from the cell; and where necessary
- 25 growing the transgenic plant for a time and under conditions sufficient to permit expression of the nucleic acid sequence into a plant hydroxyjasmonic acid sulfotransferase, preferably a 11- or 12-hydroxyjasmonic acid sulfotransferase.

30 The details of the construction of transgenic plants are known to those skilled in the art of plant genetic engineering and do not differ in kind from those practices which have previously been demonstrated to be effective in tobacco,

petunia and other model plant species (e.g. electroporation, microprojectile bombardment, Agrobacterium-mediated transfer or insertion via DNA or RNA viruses). One skilled in the art will immediately recognize the variations applicable to the methods of the present invention, such as increasing or decreasing the 5 expression of the sulfotransferase naturally present in a target plant leading to modulation of flowering to this plant. The present invention, therefore, extends to all transgenic plants containing all or part of the nucleic acid sequence of the present invention, or antisense forms thereof and/or any homologues or related forms thereof and in particular those transgenic plants which exhibit altered 10 flowering properties.

The transgenic plants may contain an introduced nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding a hydroxyjasmonic acid sulfotransferase. Generally, the nucleic acid would be stably introduced into the plant genome, although the present invention 15 also extends to the introduction of a hydroxyjasmonic acid sulfotransferase nucleotide sequence within an autonomously-replicating nucleic acid sequence such as a DNA or RNA virus capable of replicating within the plant cell. The invention also extends to cut flowers and seeds from such transgenic plants.

20 A further aspect of the present invention is directed to an isolated plant hydroxyjasmonic acid sulfotransferase, and more particularly to an isolated hydroxyjasmonic acid sulfotransferase selected from the group of:

- 25 a) an enzyme whose amino acid sequence is represented by SEQ ID NO 3 or SEQ ID NO 4; and
- b) functional homologues of enzyme a), isolated from a plant or derived from enzyme a) by substitution, deletion or addition of one or several amino acids in the amino acid sequences defined in a), and having similar biological activity or function(s).

These enzymes may be purified from plants or produced with routine 30 recombinant techniques using SEQ ID NO 1, SEQ ID NO 2, or portion(s) thereof. Various methods of purification and molecular biology techniques for producing recombinant proteins are described in the art such that a skilled technician could

obtain these enzymes without large amounts of trial and error, or complicated experimentation. Isolated hydroxyjasmonic acid sulfotransferase will provide a source of material for research to develop, for example, more active enzymes and to produce antibodies binding with affinity thereto.

5 Accordingly, a related aspect of the invention is directed to antibodies binding with affinity to one or more of the above mentioned hydroxyjasmonic acid sulfotransferases. Persons skilled in the art are aware that antibodies can be made against virtually any protein and should be capable of producing such antibodies using conventional techniques. Antibodies binding to hydroxyjasmonic
10 acid sulfotransferases could be particularly useful in flowering retardation compositions and also for studying the biological activity of this type of enzymes.

EXAMPLES

The following examples are illustrative of the wide range of applicability of
15 the present invention. The invention is not restricted to the control of flowering in *Arabidopsis thaliana* but can be applied to various plant species. It should readily occur that the recognition of activation or retardation of flowering using the compositions, and methods according to the present invention in connection with other plants not specifically illustrated herein, is readily within the capabilities of
20 one skilled in the art. The following examples are intended only to illustrate the invention and are not intended to limit its scope. Modifications and variations can be made therein without departing from the spirit and scope of the invention.

The following experimental procedures and materials were used for the examples set forth below.

25

A) Materials And Methods

Growing of plants

A. *thaliana* plants of ecotype Columbia (ColO) and C24 were used for this study. The plants were grown in soil in a growth chamber during a 16-hour
30 photoperiod, at a day-time temperature of 24 °C and a night-time temperature of 20 °C. For some experiments, the plants were grown in magenta boxes under sterile conditions according to the following protocol. Seeds of *Arabidopsis*

thaliana were sterilized for 5 minutes in a solution containing 1.5% sodium hypochlorite and 0.02% SDS, and washed five times in sterile water. Seeds were vernalized for four days at 4 °C. Seeds were then spread on agar-solidified medium containing Murashige and Skoog salts, 1% sucrose and vitamins.

5

Studies using a vector:

For transgenic studies a EcoR1-HindIII cassette, from the plasmid pBI-525 comprising two CaMV 35S promoters in tandem followed by an AMV translational enhancer and a NOS terminator, was ligated to the plasmid pBI-101 which was 10 previously digested with the same restriction endonucleases. The resulting vector called pBI-101-525 contained two CaMV 35S minimal promoters in tandem followed by an AMV translational enhancer, a NOS terminator and a kanamycin 15 resistance gene. *AtST2a* cDNA (SEQ ID NO 1; Fig. 7) was cloned both in the sense and the antisense orientation at the BaMHI site in a polylinker lying downstream of the AMV enhancer. Various other promoters may be used to drive the expression of an exogenous gene in a plant. For example the ubiquitin promoter may be used for constitutive expression. Alternatively, inducible promoters may also be used such as the ethanol-inducible promoter or the glucocorticoid-inducible promoter.

20

Agrobacterium transformation:

A. tumefaciens strain GV3101 pMP90 was transformed with the *AtST2a*-pBI-101-525 sense and antisense constructs by the method described in Gynheung *et al.* (1988) Biology Manual, A3:1-19.

25

Arabidopsis transformation:

A. *thaliana* plants of ecotype Columbia (ColO) were transformed with Agrobacterium containing the *AtST2a* gene in the sense orientation by the vacuum infiltration method as described previously in Benchtold *et al.* (1993), CR Acad. 30 Sci. Paris, Life Sciences, 316: 1194. A. *thaliana* plants of ecotype C24 were transformed with the pBI-101-525 vector containing the *AtST2a* gene in the antisense orientation by the root explant method as described in Valvekans *et al.*

(1988) Proc Natl Acad Sci USA, 85: 5536. Seeds were collected from the T₀ plants, their surface was sterilized and transformants were selected on MS salt medium containing vitamins and supplemented with 50 µg/ml of kanamycin. For phenotypic analysis of the transgenic plants, the T₂ or T₃ seeds were vernalized 5 for four days at 4 °C. Seeds were then spread on agar-solidified medium containing Murashige and Skoog salts, 1% sucrose and vitamins. Alternatively, the vernalized seeds were planted in soil and grown in a growth chamber under a 16-hour photoperiod, at a day temperature of 24 °C and a night temperature of 20 °C.

10 Western blot of protein extracts

Protein extracts from wildtype and transgenic plants were subjected to 12% SDS-PAGE. Following electrophoresis, the proteins were transferred to nitrocellulose membranes using a Bio-Rad™ semidry transblot apparatus according to the manufacturer instructions. Blots were incubated with rabbit anti-15 ATST2a primary antibodies. Immunodetection was carried on with alkaline phosphatase-conjugated anti rabbits antibodies and the immunodetection kit from Bio-Rad™.

20 Quantification of endogenous levels of 12-hydroxyjasmonate and 12-hydroxyjasmonate sulfate from Arabidopsis plants

i) 12-hydroxyjasmonate

Fresh plant material (1g) was homogenized with 10 ml methanol and 100 ng 12-(²H₃)OAc-jasmonate as internal standard, the filtrate was evaporated and acetylated with Py/Ac₂O at 20 °C overnight. The evaporated mixture was 25 loaded on a 3 ml DEAE-Sephadex™ A25 columns (Acetate-form, methanol) and the column washed with 3 ml of methanol. After washing with 3 ml of 0.1 M acetic acid in methanol, fractions eluted with 5 ml of 1 M acetic acid in methanol were collected, evaporated and separated on preparative HPLC and analyzed by GC-MS.

30 HPLC: Eurospher™ 100-C₁₈, (5 µm, 250 x 4 mm), elution with a mixture methanol - 0.2 % acetic acid in H₂O (1 : 1) at a flow rate of 1 ml min⁻¹, UV detector 210 nm, fractions between R_t 5-6.5 min were evaporated.

Derivatization: Samples were dissolved in 200 µl CHCl₃/N,N-diisopropylethylamine (1 : 1) and derivatized with 10 µl pentafluorobenzylbromide at 20 °C overnight. The evaporated samples were dissolved in 5 ml n-hexane and passed through a SiOH-column (500mg; Machery-Nagel™). The pentafluorobenzyl esters were eluted with 7 ml n-hexane / diethylether (2 : 1), evaporated, dissolved in 100 µl MeCN and analysed by GC-MS

GC-MS: (GCQ Finnigan™), 70 eV, NCI, ionization gas NH₃, source temperature 140°, column Rtx-5 (30 m x 0.25 mm, 0.25 µm film thickness), injection temperature 250°C, interface temperature 275°; Helium 40 cm s⁻¹; splitless injection; column temperature program: 1 min 60°C, 25°min⁻¹ to 180° C, 5° min⁻¹ to 270° C, 1 min 270 °, 10° min⁻¹ to 300°, 25 min 300°.

ii) 12-hydroxyjasmonic acid sulfate

The negative ion electrospray (ES) mass spectra were obtained from a Finnigan™ MAT TSQ 7000 instrument (electrospray voltage 4 kV; heated capillary temperature 220 °C; sheath gas: nitrogen) coupled with a Micro-Tech Ultra-Plus MicroLC™ system equipped with a RP18-column (4 µm, 1x100 mm, Ultrasep™). For the HPLC a gradient system was used starting from H₂O:CH₃CN 90:10 (each of them containing 0.2% HOAc) to 10:90 within 15 min followed by a 10 min isocratic period at a flow rate of 70 µl min⁻¹. The collision-induced dissociation (CID) mass spectra during the HPLC run were performed with a collision energy of 30 eV; collision gas: argon, collision pressure: 1.8 x 10⁻³ Torr. All mass spectra are averaged and background subtracted.

B) RESULTS

Example 1: Flowering induction by treating *A. thaliana* plants with 12-hydroxyjasmonic acid

Arabidopsis plants of ecotype Colombia (Col0) were grown in magenta boxes containing phytoagar and vitamins in a growth chamber under a sixteen hour photoperiod at a day-time temperature of 24 degrees and a night-time temperature of 20 degrees for a period of 18 days. The plants were then treated

with 10 μ M of 12-hydroxyjasmonic acid (Fig. 2B) or with water as a negative control (Fig 2A) for a period of 6 days.

As seen in Figure 2B, plants treated with 12-hydroxyjasmonate flowered earlier (2 days) than the plants treated with water alone. Despite the fact that a 5 treatment with 12-hydroxyjasmonic induces the hydroxyjasmonic acid sulfotransferase, early flowering is observed in the treated plants. The early flowering phenotype might be amplified if the treatment is coupled with an inhibitor of the hydroxyjasmonic acid sulfotransferase.

These results are of great economic importance since they show that it is 10 possible to induce flower formation by the exogenous application of 12-hydroxyjasmonate and/or others compounds of the jasmonate family to crop plants. Therefore it shows that one may induce early flowering when required by a simple application of a selected flower inducer to plants, particularly 12-hydroxyjasmonate.

15

Example 2: Transgenic plants flowering tardily

In this example, *A. thaliana* plants genetically modified were created by inserting therein a nucleic acid molecule encoding the *AtST2a* gene in the sense orientation under the control of a constitutive promoter. The results demonstrate 20 that a higher endogenous expression of the hydroxyjasmonic acid sulfotransferase encoded by this gene is effective to delay flowering.

Figure 3 shows the phenotype of wild type non transgenic Col0 *Arabidopsis* plants (WT) as compared to transgenic plants expressing the *AtST2a* gene under the control of the CaMV35S promoter 27 days after germination (S5, S6, S9, and 25 S16). As shown in Figure 3, expression of *AtST2a* gene in transgenic *Arabidopsis thaliana* affects flowering time since all the transgenic lines exhibited delayed flowering as compared with non-transformed plants.

Fig. 4 shows a Western blot of protein extracts of these plants probed with anti-*AtST2a* antibodies. This figure clearly shows that the length of the delay is 30 correlated with the level of expression of the transgene. This suggests that it is possible to vary the length of the delay by selecting transgenic lines expressing *AtST2a* at different levels. Delaying flowering time results in increased vegetative

growth and biomass which is a major advantage for crop such as lettuce, carrot, cabbage, sugar cane, sugar beet, to mention a few.

Table 1 hereinbelow also shows that a higher endogenous expression of the hydroxyjasmonic acid sulfotransferase results in higher endogenous level of 5 12-hydroxyjasmonate sulfate in the transgenic line S9.

TABLE 1:

	Wildtype (WT)	Transgenic (S9)
12-hydroxyjasmonate sulfate	211 peak area/g	2234 peak area/g

Example 3: Transgenic plants flowering early in non-inductive flowering conditions

10 In this example, *A. thaliana* plants genetically modified were created by inserting therein a nucleic acid molecule encoding the *AtST2a* gene in the antisense orientation under the control of a constitutive promoter. The results demonstrate that a lower endogenous expression of the hydroxyjasmonic acid sulfotransferase is effective to induce flowering.

15 Figure 5 shows the phenotype of wild type *Arabidopsis* plants of ecotype C24 (WT) as compared to transgenic plants expressing the *AtST2a* gene in the antisense orientation under the control of the CAMV35S promoter (TL 7-2-5). In this experiment, the plants were grown under short days which is non-inductive for flowering in *Arabidopsis thaliana*. Under these conditions the wildtype plants will 20 flower after approximately 95 days of vegetative growth. The photograph was taken 65 days after germination and shows clearly an early flowering phenotype for the transgenic plants. As shown in this figure, inhibition of regular expression of the *AtST2a* gene in transgenic *Arabidopsis thaliana* affects flowering time since all the transgenic lines exhibited early flowering as compared with non-transformed 25 plants.

Table 2 hereinbelow also shows that a lower endogenous expression of the hydroxyjasmonic acid sulfotransferase results in a higher endogenous level of 12-hydroxyjasmonate and in a lower endogenous level of 12-hydroxyjasmonate sulfate in plants.

TABLE 2:

	Wildtype (WT)	Transgenic (TL 7-2-5)
12-hydroxyjasmonate	7.7 ng/g	54.1 ng/g
12-hydroxyjasmonate sulfate	990 peak area/g	448 peak area/g

Interestingly, apart from early flowering, the growth behavior and the size of the transgenic plants could not be distinguished from the non-transformed control
5 plants.

Example 4: Transgenic plants flowering early under favorable flowering conditions

Treatment with methyljasmonic acid of wild type *Arabidopsis* plants grown
10 under favorable flowering day time conditions leads to elevated endogenous levels
of both jasmonic acid and 12-hydroxyjasmonic acid (data not shown), conditions
which should favor flowering. However, flowering was induced in an extent lower
than what was anticipated (data not shown). As it will be explained hereinafter, a
15 highly probable explanation for these results is that *AtST2a* gene expression is
strongly induced under these favorable flowering day time conditions when treated
with methyljasmonate thereby blocking the positive effects of the increase level of
12-hydroxyjasmonic acid.

To confirm this hypothesis, 15 days old *A. thaliana* plants and transgenic
plants expressing the *AtST2a* gene in the antisense orientation under the control
20 of a constitutive promoter were treated with 50 μ M methyljasmonic acid for a
period of nine days, and the plants were grown under favorable flowering day time
conditions.

Figure 6 shows the effect of methyljasmonic acid treatment on the
phenotype of wild type non transgenic C24 *Arabidopsis* plants (WT C24) as
25 compared to transgenic plants expressing the *AtST2a* in the antisense orientation
under the control of the CAMV35S promoter (TL 7-2-5), 24 days after germination.
As shown in this figure, expression of *AtST2a* in the antisense orientation results

in lowered levels of the *AtST2* protein and allows the transgenic plants to flower early in presence of methyljasmonic acid.

This confirms that it is preferable, under certain conditions, to genetically modify a plant to induce its flowering prior to apply thereto a product further inducing its flowering.

Example 5: *AtST2a* gene expression is regulated by 12-hydroxyjasmonate

Fifteen days-old *Arabidopsis* plants (Col0) were grown in magenta boxes in presence or in absence of 12-hydroxyjasmonate for a period of 24 hours. At the end of the incubation period, the plants were frozen in liquid nitrogen, ground to a fine powder and total mRNAs were extracted using the kit from the company Qiagen™. The mRNA extracts were resolved by agarose gel electrophoresis, and transferred by capillarity to a nylon membrane. The blot was probed with the sequence encoding *AtST2a*.

The results presented in Figure 11 show that 12-hydroxyjasmonic acid induces the expression of the *AtST2a* gene and that the level of expression is proportional to the amount of inducer. Furthermore, the results show that the level of expression is very low in untreated plants. The induction of *AtST2a* expression by its substrate suggests that the level of 12-hydroxyjasmonic acid present in the plant is tightly controlled. This result is not surprising considering the important role of 12-hydroxyjasmonic acid in the induction of flowering.

Example 6: Expression of *AtST2a* is under the control of photoperiod.

Fifteen days old *Arabidopsis* plants grown under long day conditions were transferred in the dark. At different time intervals, plants were collected, frozen in liquid nitrogen, ground to a fine powder and total mRNAs were extracted using a kit from the company Qiagen™. The mRNA extracts were resolved by agarose gel electrophoresis, and transferred by capillarity to a nylon membrane. The blot was probed with the sequence encoding *AtST2a*.

The results presented in Figure 12 show that expression of *AtST2a* increases with time when the plants are kept in the dark reaching significant levels after 8 hours of dark treatment. This result suggests that plants monitor

photoperiod by modulating the level of 11- and 12-hydroxyjasmonic acids. When the plants are grown under short day conditions, the increased level of expression of *AtST2a* leads to the sulfonation of 11- and 12-hydroxyjasmonic acids resulting in delayed flowering. When the plants are grown under long day conditions, 5 *AtST2a* is not expressed and the levels of 11- and 12-hydroxyjasmonic acids increase resulting in an early flowering time.

C) CONCLUSION

As shown in the above examples, *AtST2a* and *AtST2b* gene expression is 10 induced after the application of 12-hydroxyjasmonate with a maximum of six hours after the beginning of the treatment. This pattern of induction demonstrates that the level of 12-hydroxyjasmonic acid is tightly regulated *in vivo* suggesting that 12-hydroxyjasmonic acid plays an important role in the plant. *AtST2a* and *AtST2b* gene expression is also induced when the plants are grown in the dark. The kinetic 15 of accumulation of *AtST2a* and *AtST2b* mRNA is slow with a maximum observed after 12 hours in the dark. Furthermore, there is a fast decrease in *AtST2a* and *AtST2b* mRNA levels when the plants are transferred back to light. Taken together, these results suggest that the biological function of *AtST2a* and *AtST2b* is to modulate the activity of 12-hydroxyjasmonic acid and 11-hydroxyjasmonic 20 acid in relation to the photoperiod. The model presented in the section "General overview of the invention" integrates the different results obtained and tries to explain the role of the hydroxylated jasmonates and of the *AtST2a* and *AtST2b* genes in the control of flowering time. According to this model, 11- and 12-hydroxyjasmonic acids are synthesized slowly into the leaves from jasmonic acid 25 or from early fatty acids precursors. The accumulation of these metabolites up to a threshold value induces flowering. When the plants are growing under short day time conditions, *AtST2a* and/or *AtST2b* will be expressed during the night and will inactivate 11- and 12-hydroxyjasmonic acids by sulfonation. This mechanism will retard flowering time until the photoperiod is favorable. When the plants are 30 growing under long day time conditions, the level of expression of *AtST2a* and/or *AtST2b* is low and 11- and 12-hydroxyjasmonic acids will accumulate to levels sufficient to induce flowering.

While several embodiments of the invention have been described, it will be understood that the present invention is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention, following in general the principles of the invention and including such 5 departures from the present disclosure as to come within knowledge or customary practice in the art to which the invention pertains, and as may be applied to the essential features hereinbefore set forth and falling within the scope of the invention or the limits of the appended claims.

CLAIMS:

1. A method for modulating flowering in a plant, comprising modifying in said plant the endogenous level of at least one compound selected from the group consisting of jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, sulfate ester of 12-hydroxyjasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, sulfate ester of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, sulfate ester of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, glucoside of 11-hydroxymethyljasmonic acid, sulfate ester of 11-hydroxymethyljasmonic acid, and mixtures thereof.
- 15 2. The method of claim 1, wherein flowering of said plant is induced by increasing in said plant the endogenous level of at least one flowering inducing compound selected from the group consisting of jasmonic acid, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid, said flowering induction and said endogenous level increase being compared to a corresponding plant wherein the endogenous level of said at least one compound has not been modified.
- 30 3. The method of claim 2, wherein the endogenous level of said at least one flowering inducing compound is increased by a method selected from the group consisting of:

AMENDED SHEET

- a) applying to said plant at least one of said flowering inducing compounds and/or salts thereof;
- b) applying to said plant at least one inhibitor of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic; and
- 5 c) applying to said plant at least one stimulator of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid.

4. The method of claim 2, wherein the endogenous level of said at least one flowering inducing compound is increased by:

- 10 a) increasing in said plant the endogenous level of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid; and/or
- b) lowering in said plant the endogenous level of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic.

15 5. The method of claim 4, wherein the endogenous level of the sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic is lowered subsequently to a genetic modification of said plant.

6. The method of claim 5, wherein said genetic modification comprises the 20 step of inhibiting the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or of *AtST2b*.

7. The method of claim 6, wherein said gene expression is inhibited by expressing into said plant an exogenous sequence coding for a nucleic acid 25 sequence antisense to said gene.

8. The method of claim 7, wherein said exogenous sequence is expressed under the control of a constitutive or an inducible promoter.

30 9. The method of any one of claims 5 to 8, wherein said plant is transgenic.

AMENDED SHEET

10. The method of claim 3, wherein said plant has been genetically modified to flower early prior application thereto of said flowering compound(s), said sulfotransferase inhibitor(s) and/or said hydroxylase stimulator(s).

5 11. The method of any one of claims 2 to 10, wherein said plant is selected from crop plants.

12. A plant genetically modified to flower early when compared to a corresponding plant not genetically modified, said genetically modified plant 10 having an increased endogenous level of jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic 15 acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid, when compared to said corresponding non-genetically modified plant.

13. The plant of claim 12, wherein said genetic modification comprises:
20 a) increasing in said genetically modified plant the endogenous level an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid; and/or b) lowering in said genetically modified plant the endogenous level of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic.

25 14. The genetically modified plant of claim 12 or 13, wherein said genetic modification comprises inhibiting the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or of *AtST2b*.

30 15. The genetically modified plant of claim 13, wherein the endogenous level of the sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-

AMENDED SHEET

hydroxyjasmonic is lowered by expressing into said plant an exogenous nucleic acid sequence, said exogenous nucleic acid sequence encoding: i) for a nucleic acid sequence antisense to a gene encoding at least one of said sulfotransferases; or ii) for a nucleic acid sequence antisense to a portion of said 5 gene.

16. The genetically modified plant of claim 15, wherein said exogenous sequence is expressed under the control of a constitutive or inducible promoter.
- 10 17. The genetically modified plant of any one of claims 12 to 16, wherein said plant is transgenic.
- 15 18. A cut flower from the genetically modified plant of any one of claims 12 to 17.
19. A composition for inducing flowering in a plant comprising a flowering inducing effective amount of a compound selected from the group consisting of, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, glucoside of 11-hydroxymethyljasmonic acid, salts thereof, and mixtures thereof, in combination 20 with a diluent or a carrier such that an induction in flowering of said plant occurs 25 when compared to a corresponding plant in the absence of said composition.
20. The composition of claim 19, further comprising a compound selected from the group consisting of fertilizers, growth regulators, fungicides, insecticides, 30 emulsifying agents and mixtures thereof.

21. The method of claim 1, wherein flowering of said plant is delayed by lowering in said plant the endogenous level of at least one compound selected from the group consisting of jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-5 isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-10 hydroxymethyljasmonic acid, and glucoside of 12-hydroxymethyljasmonic acid, said flowering delay and said lower endogenous level being compared to a corresponding plant wherein the endogenous level of said at least one compound has not been modified.

22. The method of claim 21, wherein the endogenous level of said at least one compound is lowered by:

- applying to said plant an inhibitor and/or an inactivator of at least one of said compounds;
- applying to said plant at least one stimulator of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic; and/or
- applying to said plant at least one inhibitor of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid.

23. The method of claim 21, wherein the endogenous level of said at least one compound is lowered by:

- lowering in said plant the endogenous level of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid; and/or
- increasing in said plant the endogenous level of a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-hydroxyjasmonic acid.

30 24. The method of claim 23, wherein the endogenous level of said sulfotransferase is increased subsequently to a genetic modification in the genome of said plant.

AMENDED SHEET

25. The method of claim 24, wherein said genetic modification comprises the steps of increasing the expression of at least one gene selected from the group consisting of *AtST2a*, *AtST2b* and functional homologues of *AtST2a* or of *AtST2b*.

5

26. The method of claim 25, wherein said gene expression is increased by placing said gene under the control of a constitutive or of an inducible promoter.

10

27. The method of any one of claims 21 to 26, wherein said plant is transgenic.

15

28. The method of claim 22, wherein said plant has been genetically modified to flower lately prior application thereto of said compound(s), said sulfotransferase stimulator(s) and/or said hydroxylase inhibitor(s).

20

29. A plant genetically modified to flower tardily when compared to a corresponding plant not genetically modified, said genetically modified plant having a lowered endogenous level of at least one compound selected from the group consisting of jasmonic acid, jasmonic acid-tyrosine conjugate, jasmonic acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, methyljasmonic acid, 12-hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid, when compared to said corresponding non-genetically modified plant.

AMENDED SHEET

30. The plant of claim 29, wherein said genetic modification comprises:

a) lowering in said genetically modified plant the endogenous level of an hydroxylase hydroxylating jasmonic acid and/or methyljasmonic acid; and/or

b) increasing in said genetically modified plant the endogenous level a sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-
5 hydroxyjasmonic.

31. The genetically modified plant of claims 29 or 30, wherein said genetic

modification comprises increasing the expression of at least one gene selected

10 from the group consisting of *AtST2a*, *AtST2b* and functional homologues of
AtST2a or *AtST2b*.

32. The genetically modified plant of claim 30, wherein the endogenous level of

the sulfotransferase sulfonating 12-hydroxyjasmonic acid and/or 11-
15 hydroxyjasmonic is increased by expressing into said genetically modified plant a

nucleic acid sequence encoding said sulfotransferase under the control of a
constitutive or an inducible promoter.

33. The genetically modified plant of any one of claims 29 to 32, wherein said

20 plant is transgenic.

34. A composition for delaying flowering in a plant comprising a flowering

delaying effective amount of an inhibitor or of an inactivator of a compound
selected from the group consisting of jasmonic acid-tyrosine conjugate, jasmonic

25 acid-tryptophan conjugate, jasmonic acid-phenylalanine conjugate, jasmonic acid-
isoleucine conjugate, jasmonic acid-leucine conjugate, jasmonic acid-valine
conjugate, 12-hydroxyjasmonic acid, glucoside of 12-hydroxyjasmonic acid, 12-

hydroxymethyljasmonic acid, glucoside of 12-hydroxymethyljasmonic acid, 11-
hydroxyjasmonic acid, glucoside of 11-hydroxyjasmonic acid, 11-

30 hydroxymethyljasmonic acid, and glucoside of 11-hydroxymethyljasmonic acid, in
combination with a diluent or a carrier such that a delay in flowering of said plant

occurs when compared to a corresponding plant in the absence of said composition.

35. The composition of claim 34, further comprising a compound selected from 5 the group consisting of fertilizers, growth regulators, fungicides, insecticides, emulsifying agents and mixtures thereof.

36. An isolated or purified nucleic acid molecule encoding a plant 11-hydroxyjasmonic acid or 12-hydroxyjasmonic acid sulfotransferase.

10 37. The isolated nucleic acid molecule of claim 36, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1, nucleotide sequences having at least 50% similarity with SEQ ID NO:1, SEQ ID NO:2, nucleotide sequences having at least 50% similarity with SEQ ID NO:2 and 15 nucleotide sequences complementary thereto.

38. The isolated nucleic acid molecule of claim 36, comprising a nucleotide sequence which hybridizes under low stringency conditions to a nucleotide sequence selected from 20 the group consisting of SEQ ID NO:1, a complementary strand of SEQ ID NO:1, SEQ ID NO:2 and a complementary strand of SEQ ID NO:2.

39. The isolated nucleic acid molecule of any one of claims 36 to 38, wherein 25 the hydroxyjasmonic acid sulfotransferase is of *Arabidopsis thaliana* origin.

40. A vector comprising the nucleic acid molecule of any one of claims 36 to 39.

41. The vector of claim 40, wherein the vector is capable of replication and 30 expression in a plant cell.

42. A transgenic plant comprising the nucleic acid molecule of any one of claims 36 to 39.

AMENDED SHEET

43. A method for producing a transgenic plant capable to flower early, said method comprising the steps of:

- a) introducing into a cell of a suitable plant an exogenous nucleic acid molecule comprising a sequence of nucleotides antisense to a sequence encoding a plant hydroxyjasmonic acid sulfotransferase;
- b) regenerating a transgenic plant from the cell; and
- c) growing said transgenic plant for a time and under conditions sufficient to inhibit expression of the hydroxyjasmonic acid sulfotransferase.

10

44. The method of claim 43, wherein the exogenous nucleic acid molecule comprises a nucleotide sequence antisense to a nucleotide sequence selected from the group consisting of SEQ ID NO:1, nucleotide sequences having at least 50% similarity with SEQ ID NO:1, SEQ ID NO:2 and nucleotide sequences having at least 50% similarity with SEQ ID NO:2.

15

45. A method for producing a transgenic plant capable to flower tardily, said method comprising the steps of:

- a) introducing into a cell of a suitable plant an exogenous nucleic acid molecule encoding a plant hydroxyjasmonic acid sulfotransferase;
- b) regenerating a transgenic plant from the cell; and
- c) growing said transgenic plant for a time and under conditions sufficient to permit expression of the nucleic acid sequence into an hydroxyjasmonic acid sulfotransferase.

20

46. The method of claim 45, wherein the exogenous nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO:1, nucleotide sequences having at least 50% similarity with SEQ ID NO:1, SEQ ID NO:2 and nucleotide sequences having at least 50% similarity with SEQ

30

ID NO:2.

47. The method of any one of claims 43 to 46, wherein the hydroxyjasmonic acid sulfotransferase is a 11- or a 12- hydroxyjasmonic acid sulfotransferase.

48. An isolated or purified polypeptide having the biological activity of a plant 5 11-hydroxyjasmonic acid or 12-hydroxyjasmonic acid sulfotransferase.

49. The polypeptide of claim 48, encoding a sulfotransferase enzyme selected from the group consisting of:

- a) an enzyme whose amino acid sequence is represented by SEQ ID NO: 3 or 10 SEQ ID NO: 4; and
- b) functional homologues of enzyme a) isolated from a plant, or derived from enzyme a) by substitution, deletion or addition of one or several amino acids in the amino acid sequences defined in a) and having similar biological activity or function(s).

15

50. An antibody binding with affinity to a polypeptide as defined in claim 48 or 49.

51. The antibody of claim 50 used for delaying flowering in a plant.

20

AMENDED SHEET

AMENDED SHEET

Empfangszeit 21. Sep. 20:31

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02589 A2

(51) International Patent Classification⁷: C12N 15/82, 15/54, 9/10, C07K 16/40, A01H 5/00

(21) International Application Number: PCT/CA00/00801

(22) International Filing Date: 6 July 2000 (06.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,274,873 6 July 1999 (06.07.1999) CA

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants and

(72) Inventors: VARIN, Luc [CA/CA]; 4618 De Lanaudière, Montréal, Québec H2J 3P7 (CA). GIDDA, Satinder [CA/CA]; 8854 Giroux, Lasalle, Québec H8R 3N8 (CA).


(74) Agent: ROBIC; 55 St-Jacques, Montréal, Québec H2Y 3X2 (CA).

Published:

— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

(54) Title: METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MODULATING FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER EARLY AND TARDILY



WO 01/02589 A2

(57) Abstract: The present invention relates to methods, compositions and genetic sequences for modulating flowering in plants and to plants genetically modified to flower early and to plants genetically modified to flower tardily. More particularly the present invention provides among others a genetic sequence encoding for a hydroxyjasmonic acid sulfotransferase and methods for producing transgenic plants using such a sequence.

1/6




Figure 1A




Figure 1B



Figure 2A



Figure 2B

10/019931

PCT/CA00/00801

WO 01/02589

2/6




Figure 3




Figure 4

10/01/9931

PCT/CA00/00801

WO 01/02589

3/6




Figure 5



Figure 6

10/01/9931

WO 01/02589

PCT/CA00/00801

4/6

Figure 7

SEQ ID NO 1:

ATGGCTACCTCAAGCATGAAGAGCATTCCAATGGCGATCCCAAGTTCTCCATGTGTCAC
AAGCTCGAGCTCCTAAAGAAGGCAAAACTCGCGACGTCCGAAAGCCGAAGAAGATGAA
GGGCTAAGCTGCGAGTCCAAGAGATGTTGGATTCTCTTCTTAAGGAGAGAGGATGGAGA
ACTCGTTACCTTACCTATTCCAAGGGTTTGGTCCAAGCCAAAGAGATTCAAGCCATC
ATGTCTTCAAAAACATTCCAATCCCTCGAAAACGACGTCGTTCTGCCACCACACCT
AAATCCGGTACAACCTGGCTAAAGCTTAACCTTACCATCCTTAACCGTCACCGGTTT
GATCCGGTTGCCTCGAGTACCAACCACCCCTTTCACTTCCAACCCCTCATGACCTTGT
CCTTCTCGAGTACAAGCTTACGCCAACGGAGATGTTCCGATCTCTCGGGTAGCC
AGTCCAAGAACGTCGCAACCCACTTACCGTTCGGTTCCCTAAAGGAAACGATCGAGAAA
CCCGGTGTGAAGGTCGTGTACTTGTGCCGGAACCCGTTGACACATTCATCTCTCGTGG
CATTACACCAACAACATCAAATCCGAGTCAGTGAGCCCAGTCTGCTAGACCAAGCTTT
GATCTGTATTGCCGGGGAGTGATCGGGTTGGCCCGTTGGAACACATGTTGGGATAC
TGGAGAGAGAGCTTGAAGAGACCAGAGAAAGTCTCTTTAAGGTACGAGGATCTAAA
GACGACATCGAGACCAACTTGAAGAGGGCTGCAACTTCTTAGAGCTTCCTTCACCGAA
GAAGAGGAACGAAAGGGAGTTGTGAAGGCTATGCCGAGCTGTAGCTCGAGAACATCG
AAGAAGTTGGAGGTGAACAAGTCAAACAGTCATCAAGAACATTGAGAACATCGATTCTG
TTTCGGAAAGGAGAAGTGAGTGATTGGTTAACTATTGTACCTTCACAAGTGGAAAGA
TTGTCAGCCTTAGTGGATGACAAGTTAGGTGGATCTGGTCTCACTTCAGGTTGAGC

Figure 8

SEQ ID NO 3:

MATSSMKSIPMAIPSFSMCHKLELLKEGKTRDVPKAEEDEGLSCEFQEMLDSPKERGWR
TRYLYLFQGFWCQAKEIQAIMSFQKHQSLENDVVLATIPKSGTTWLKALTFTILNRHRF
DPVASSTNHPLFTSNPHDLVPFFEYKLYANGDVPDLSGLASPRTFATHLPFGSLKETIEK
PGVKVVYLCRNPFDTFISSLWHYTNNIKSESVSPVLLDQAFDLYCRGVIGFGPFWEHMLGY
WRESLRPEKVFFLRYEDLKDDIETNLKRLATFLELPTEEEERKGVVKAIaelcsfenL
KKLEVNKSNKSIKNFENRFLFRKGEVSDWVNYLSPSVERLSALVDDKLGGSLTFRLS

5/6


Figure 9**SEQ ID NO 2:**

ATGGCGATCCCAAGTTCTCATGTGTACAAGCCGAGCTCCTAACCGAAGGCAAAAGC
 GAAGGCCAAGAAGAAGAAGGGCTAACGCTACGAGTTCCAAGAGATGTTGGACTCTCTCCT
 AAGGAGAGAGGACGGAGAAATCGTTACCTTACTTATTCCAAGGGTTCGGTGCCAAGCT
 AAGGAGATTCAAGCTATCACGTCTTCCAAAACATTTCAGTCCCTCCAGACGACGTT
 GTCCTCGCCACCATACTAAATCTGGCACAAACCTGGTAAAAGCTTAACTTCACCATC
 CTTACCCGTCATCGGTTGATCCGGTTCTCATCAAGTTCCGACCACCCCTTCTCACA
 TCCAACCCCTCACGACCTCGTACCTTCTCGAGTACAAGCTTACGCCAACGAAATGTT
 CCCGATCTCTCGGGCTAGCCAGTCCAAGAACATTGCAACCCACGTACCGTTCGGTGC
 CTTAAGGATTCGGTCGAGAATCCCAGTGTGAAGGTTGTACCTGTGCCGGAACCGTT
 GACACATTCATCTCCATGTGGCATTACATCAACAAACATCACCTCCGAGTCAGTGAGCGCA
 GTCTTGCTAGACGAAGCTTGATCTATATTGCCGGGGATTACTGATCGGATTGGCCCG
 TTTGGGAACACATGTTGGGATACTGGAGAGAGAGCTTGAAGAGGCCAGAGAAAGTCTTA
 TTTTAAAGTACGAGGATCTCAAAGAAGACATCGAGACCAACTTGAAGAAGCTAGCAAGT
 TTCTTAGGACTTCCTTCACCGAAGAAGAGGAACAAAAGGGAGTTGTGAAAGCTATCGCT
 GATCTGTGTAGCTTGAGAATCTGAAGAAGTTGGAGGTGAACAAAGTCAAGCAAATTGATC
 CAGAACTATGAGAACCGTTCTTGTGAAAGGAGAAGTGAGTGAGTTGGTTAACTAT
 TTGTCGCCATCACAAGTGGAAAGATTGTCAGCCTAGTGGATGACAAGTTAGCTGGATCT
 GGTCTCACTTCAGATTGAGT

Figure 10**SEQ ID NO 4:**

MAIPSFSMCHKPELLKEGKSEGQEEGLSYEFQEMLDLPERGRNRNRYLYLFQGFRCQA
 KEIQAITSFQKHFQSLPDDVVLATIPKSGTTWLKALTFTILTRHRFDPVSSSSDHPLLT
 SNPHDLVPFFEYKLYANGNVPDLSGLASPRTFATHVPFGALKDSVENPSVKVVYLCRNPF
 DTFISMWHYINNITSESVAVLLDEAFDLYCRGLLIGFGPFWEHMLGYWRESLRPEKVL
 FLKYEDLKEDIETNLKKLASFLGLPFTEEEEQKGVVKAIADLCSFENLKKLEVNKSSKLI
 QNYENRFLFRKGEVSDLVNYLSPSVERLSALVDDKLAGSLTFRLS


6/6



0 100 10 1 0.1

[12-hydroxyjasmonic acid]
in μ M

Fig. 11



0 4 8 12 24 48 Hours

Dark treatment

Fig. 12

Applicant or Patentee: FLORISYS INC.

Serial or Patent No.: _____ Docket No.: _____

Filed or Issued:

For: METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MUDULATING FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER EARLY AND TARDILY

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(b)) – INDEPENDENT INVENTOR**

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Sections 41 (a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled: METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MUDULATING FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER EARLY AND TARDILY

described in:

the specification filed herewith
 application serial No. 10/019,931, filed July 6, 2000 (international)
 patent No. _____, issued _____

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a non-profit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

no such person, concern, or organization
 persons, concerns or organizations listed below*

* NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

FULL NAME: FLORISYS INC.

ADDRESS: 1093 Berthe Louard, app. 301, Montréal, Québec H2M 2J6 CANADA

INDIVIDUAL

SMALL BUSINESS CONCERN

NON-PROFIT ORGANIZATION

FULL NAME _____

ADDRESS _____

INDIVIDUAL

SMALL BUSINESS CONCERN

NON-PROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such wilful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Luc VARIN

NAME OF INVENTOR




Signature of Inventor

Jan. 30, 2002

Satinder GIDDA

NAME OF INVENTOR



Signature of Inventor

January 30, 2002

NAME OF INVENTOR

Signature of Inventor

Date

Date

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I (we) hereby declare that my (our) residence, post office address and citizenship are as stated below next to my (our) name; I (we) believe that I am (we are) the original, first and sole inventor(s) (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention (Design, if applicable) entitled: **METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR MODULATING FLOWERING IN PLANTS, AND PLANTS GENETICALLY MODIFIED TO FLOWER EARLY AND TARDILY**

the specification of which (check one): is attached hereto; was filed on _____ as application serial No. _____ and was amended on (or amended through) _____ (if applicable); was filed on July 6, 2000 as International Application (PCT) No. PCT/CA00/00801 and amended on September 21, 2001 (if applicable). I (we) hereby state that I (we) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I (we) acknowledge the duty to disclose information known by me (us) to be material to the patentability of my (our) invention in accordance with Title 37, Code of Federal Regulations, § 1.56(a). I (we) hereby claim foreign priority benefits under Title 35, United States Code § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application which priority is claimed.

I (We) hereby claim foreign priority benefits under Title 35, United States Code § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application which priority is claimed.

Prior Foreign Application(s)			Priority Claimed	
2,274,873 (Number)	CANADA (Country)	06/07/1999 (Day/Month/Year Filed)	<input checked="" type="checkbox"/> YES	<input type="checkbox"/> NO
 (Number)	 (Country)	 (Day/Month/Year Filed)	 <input type="checkbox"/> YES	 <input type="checkbox"/> NO

I (we) hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I (we) acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior art application and the national or PCT international filing date of this application:

(Appl. No.)	(Filing date)	(Status – Patented, Pending or Abandoned)
(Appl. No.)	(Filing date)	(Status – Patented, Pending or Abandoned)

I (we) hereby declare that all statements made herein of my (our) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I (we) hereby appoint as my (our) attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Garabed NAHABEDIAN (Reg. No. 29,507); Thierry ORLHAC (Reg. No. 29,497); Alain PROVOST (Reg. No. 33,143); Nathalie JODOIN (Reg. No. 41,558); Louis-Pierre GRAVELLE (Reg. No. 44,429); Luc MORIN (Reg. No. 44,430); and France LECLAIRE (Reg. No. 48,115), whose professional address is 55 St Jacques, Montreal, Quebec, Canada, H2Y 3X2.

Full name of First or Sole Inventor <u>Luc VARIN</u>	Citizenship Canadian
Residence Address-Street 4618 De Lanaudière	Post Office Address-Street 4618 De Lanaudière
City Montréal	City Montréal
State or Country Zip Québec CANADA H2J 3P7	State or Country Zip Québec CANADA H2J 3P7
Date January 30, 2002	Signature 

Full name of second Inventor <u>Satinder GIDDA</u>	Citizenship Canadian
Residence Address-Street 8854 Giroux	Post Office Address-Street 8854 Giroux
City Lasalle	City Lasalle
State or Country Zip Québec CANADA H8R 3N8 2V4	State or Country Zip Québec CANADA H8R 3N8 2V4
Date January 30, 2002	Signature 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Luc VARIN *et al.*.

Assignee:

Application filed: herewith

For: METHODS, COMPOSITIONS AND GENETIC SEQUENCES FOR
MODULATING FLOWERING IN PLANTS, AND PLANTS GENETICALLY
MODIFIED TO FLOWER EARLY AND TARDILY

ASSOCIATE POWER OF ATTORNEY

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231
U.S.A.

SIR:


I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number:

KATTEN MUCHIN ZAVIS
Customer Number: 27160

RESPECTFULLY SUBMITTED

BY:

Date: February 13, 2002


Thierry ORLHAC
Registration No. 29,497

10/019931

Reg'd PCT/PTO 10 MAY 2002

SEQUENCE LISTING

<110> Varin, Luc
Gidda, Satinda

<120> Methods, compositions and genetic sequences for
modulating flowering in plants, and plants genetically
modified to flower early and tardily.

<130> ROBIC 214187

<140> 10/019,931
<141> 2000-07-06

<150> PCT WO 01/02589 A2
<151> 2000-07-06

<160> 4

<170> PatentIn Ver. 2.1

<210> 1
<211> 1077
<212> DNA
<213> Arabidopsis thaliana

<400> 1
atggctacct caagcatgaa gaggattcca atggcgatcc caagtttctc catgtgtcac 60
aagctcgagc tccttaaaga aggcaaaact cgcgcgtcc cgaaagccga agaagatgaa 120
gggctaagct gcgagttcca agagatgtt gattcttctc ctaaggagag aggtggaga 180
actcggttacc tttacccattt ccaagggttt tgggtccaaag ccaaagagat tcaagccatc 240
atgtctttcc aaaaacattt ccaatccctc gaaaacgacg tcgttctcgc caccataacct 300
aaatccggta caacctggct aaaagcttta actttcacca tccttaaccg tcaccgggttt 360
gatccgggtt cctcgagtac caaccaccct cttttcaactt ccaaccctca tgaccttgta 420
cctttcttcg agtacaagct ttacgccaac ggagatgttc ccgatctctc gggcttagcc 480
agtccaaagaa cgttcgcac ccacttaccg ttccggttccc taaaggaaac gatcgagaaa 540
cccggtgtga aggtcggtga cttgtgccgg aacccttttgc acacattcat ctcttcgtgg 600
cattacacca acaacatcaa atccgagtca gtgagccag tcttgctaga ccaagctttt 660
gatctgtatt gcccggagt gatcggtt gggccgtttt gggacacat gttggatac 720
tggagagaga gcttgaagag accagagaaa gtcttctttt taaggtacga ggatctcaa 780
gacgacatcg agaccaactt gaagaggctt gcaactttct tagagcttcc tttcaccgaa 840
gaagaggaac gaaaggaggt tggtaaggct atcgccgagc tggtagctt cgagaatctg 900
aagaagttgg aggtgaacaa gtcaaacaag tcgatcaaga actttgagaa tcgattctt 960
tttcggaaag gagaagttagt gatgggtt aactatttgc caccttcaca agtggaaaga 1020
ttgtcagcct tagtggatga caagtttaggt ggatctggtc tcactttcag gttgagc 1077

<210> 2

<211> 1041
<212> DNA
<213> Arabidopsis thaliana

<400> 2
atggcgatcc caagttctc catgtgtcac aagcccgagc tccttaagga aggcaaaagc 60
gaaggccaaag aagaagaagg gctaagctac gagttccaag agatgttggc ctctcttcct 120
aaggagagag gacggagaaa tcgttacctt tacttattcc aagggttgc gtgccaagct 180
aaggagatc aagctatcac gtctttccaa aaacatttc agtcccttcc agacgacgtt 240
gtcctcgcca ccatacctaa atctggcaca acctggttaa aagcttaac tttcaccatc 300
cttacccgtc atcggttga tccgggttcc tcataagtt ccgaccaccc tcttctcaca 360
tccaaccctc acgacacctgt acctttcttc gagtacaagc tttacgcca cggaaatgtt 420
cccgatctc cgggtctagc cagtccaaga acattcgcaa cccacgtacc gttcggtgcc 480
cttaaggatt cggtcgagaa tcccagtgtg aaggttgtgt acctgtgccg gaacccttt 540
gacacattca tctccatgtg gcattacatc aacaacatca cttccgagtc agtgagcgca 600
gtcttgctag acgaagctt tgatctatat tgccggggat tactgatcgg atttggcccg 660
ttttggaaac acatgttggg atactggaga gagagcttga agaggccaga gaaagtctta 720
tttttaaagt acgaggatct caaagaagac atcgagacca acttgaagaa gctagcaagt 780
ttcttaggac ttctttcac cgaagaagag gaacaaaagg gagttgtgaa agctatcgct 840
gatctgtgta gcttgagaa tctgaagaag ttggaggtga acaagtcaag caaattgatc 900
cagaactatg agaaccggtt cttgtttagg aaaggagaag tgagtgatt ggttaactat 960
ttgtcgccat cacaagtgga aagattgtca gccttagtgg atgacaagtt agctggatct 1020
ggtctcactt tcagattgag t 1041

<210> 3
<211> 359
<212> PRT
<213> Arabidopsis thaliana

<400> 3
Met Ala Thr Ser Ser Met Lys Ser Ile Pro Met Ala Ile Pro Ser Phe
1 5 10 15
Ser Met Cys His Lys Leu Glu Leu Leu Lys Glu Gly Lys Thr Arg Asp
20 25 30
Val Pro Lys Ala Glu Glu Asp Glu Gly Leu Ser Cys Glu Phe Gln Glu
35 40 45
Met Leu Asp Ser Leu Pro Lys Glu Arg Gly Trp Arg Thr Arg Tyr Leu
50 55 60
Tyr Leu Phe Gln Gly Phe Trp Cys Gln Ala Lys Glu Ile Gln Ala Ile
65 70 75 80
Met Ser Phe Gln Lys His Phe Gln Ser Leu Glu Asn Asp Val Val Leu
85 90 95

Ala Thr Ile Pro Lys Ser Gly Thr Thr Trp Leu Lys Ala Leu Thr Phe
 100 105 110

Thr Ile Leu Asn Arg His Arg Phe Asp Pro Val Ala Ser Ser Thr Asn
 115 120 125

His Pro Leu Phe Thr Ser Asn Pro His Asp Leu Val Pro Phe Phe Glu
 130 135 140

Tyr Lys Leu Tyr Ala Asn Gly Asp Val Pro Asp Leu Ser Gly Leu Ala
 145 150 155 160

Ser Pro Arg Thr Phe Ala Thr His Leu Pro Phe Gly Ser Leu Lys Glu
 165 170 175

Thr Ile Glu Lys Pro Gly Val Lys Val Val Tyr Leu Cys Arg Asn Pro
 180 185 190

Phe Asp Thr Phe Ile Ser Ser Trp His Tyr Thr Asn Asn Ile Lys Ser
 195 200 205

Glu Ser Val Ser Pro Val Leu Leu Asp Gln Ala Phe Asp Leu Tyr Cys
 210 215 220

Arg Gly Val Ile Gly Phe Gly Pro Phe Trp Glu His Met Leu Gly Tyr
 225 230 235 240

Trp Arg Glu Ser Leu Lys Arg Pro Glu Lys Val Phe Phe Leu Arg Tyr
 245 250 255

Glu Asp Leu Lys Asp Asp Ile Glu Thr Asn Leu Lys Arg Leu Ala Thr
 260 265 270

Phe Leu Glu Leu Pro Phe Thr Glu Glu Glu Arg Lys Gly Val Val
 275 280 285

Lys Ala Ile Ala Glu Leu Cys Ser Phe Glu Asn Leu Lys Lys Leu Glu
 290 295 300

Val Asn Lys Ser Asn Lys Ser Ile Lys Asn Phe Glu Asn Arg Phe Leu
 305 310 315 320

Phe Arg Lys Gly Glu Val Ser Asp Trp Val Asn Tyr Leu Ser Pro Ser
 325 330 335

Gln Val Glu Arg Leu Ser Ala Leu Val Asp Asp Lys Leu Gly Gly Ser
 340 345 350

Gly Leu Thr Phe Arg Leu Ser

355

<210> 4

<211> 347

<212> PRT

<213> Arabidopsis thaliana

<400> 4

Met Ala Ile Pro Ser Phe Ser Met Cys His Lys Pro Glu Leu Leu Lys
1 5 10 15

Glu Gly Lys Ser Glu Gly Gln Glu Glu Gly Leu Ser Tyr Glu Phe
20 25 30

Gln Glu Met Leu Asp Ser Leu Pro Lys Glu Arg Gly Arg Arg Asn Arg
35 40 45

Tyr Leu Tyr Leu Phe Gln Gly Phe Arg Cys Gln Ala Lys Glu Ile Gln
50 55 60

Ala Ile Thr Ser Phe Gln Lys His Phe Gln Ser Leu Pro Asp Asp Val
65 70 75 80

Val Leu Ala Thr Ile Pro Lys Ser Gly Thr Thr Trp Leu Lys Ala Leu
85 90 95

Thr Phe Thr Ile Leu Thr Arg His Arg Phe Asp Pro Val Ser Ser Ser
100 105 110

Ser Ser Asp His Pro Leu Leu Thr Ser Asn Pro His Asp Leu Val Pro
115 120 125

Phe Phe Glu Tyr Lys Leu Tyr Ala Asn Gly Asn Val Pro Asp Leu Ser
130 135 140

Gly Leu Ala Ser Pro Arg Thr Phe Ala Thr His Val Pro Phe Gly Ala
145 150 155 160


Leu Lys Asp Ser Val Glu Asn Pro Ser Val Lys Val Val Tyr Leu Cys
165 170 175

Arg Asn Pro Phe Asp Thr Phe Ile Ser Met Trp His Tyr Ile Asn Asn
180 185 190

Ile Thr Ser Glu Ser Val Ser Ala Val Leu Leu Asp Glu Ala Phe Asp

195 200 205
Leu Tyr Cys Arg Gly Leu Leu Ile Gly Phe Gly Pro Phe Trp Glu His
210 215 220
Met Leu Gly Tyr Trp Arg Glu Ser Leu Lys Arg Pro Glu Lys Val Leu
225 230 235 240
Phe Leu Lys Tyr Glu Asp Leu Lys Glu Asp Ile Glu Thr Asn Leu Lys
245 250 255
Lys Leu Ala Ser Phe Leu Gly Leu Pro Phe Thr Glu Glu Glu Gln
260 265 270
Lys Gly Val Val Lys Ala Ile Ala Asp Leu Cys Ser Phe Glu Asn Leu
275 280 285
Lys Lys Leu Glu Val Asn Lys Ser Ser Lys Leu Ile Gln Asn Tyr Glu
290 295 300
Asn Arg Phe Leu Phe Arg Lys Gly Glu Val Ser Asp Leu Val Asn Tyr
305 310 315 320
Leu Ser Pro Ser Gln Val Glu Arg Leu Ser Ala Leu Val Asp Asp Lys
325 330 335
Leu Ala Gly Ser Gly Leu Thr Phe Arg Leu Ser
340 345

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

✓ Drawings are dark.
✓ Scanned copy is best available.